BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE

CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: TUESDAY, APRIL 19, 2011

10 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 89858

INDEX

ITEM DESCRIPTION	PAGE NO
CALL TO ORDER	3
ROLL CALL	3
3. CONSIDERATION OF CIRM BUDGET FOR FISCAL YEAR 2011-2012.	5, 49
4. CONSIDERATION OF AMENDMENTS TO LOAN ADMINISTRATION POLICY.	26, 54
5. DISCUSSION OF IMPACT OF STATE BUDGET ON SALE OF BONDS ON BEHALF OF CIRM.	45
6. PUBLIC COMMENT.	NONE
7. ADJOURNMENT.	57

	DARRISTERS REPORTING SERVICE
1	TUESDAY, APRIL 19, 2011
2	10 A.M.
3	
4	CHAIRMAN GOLDBERG: CALL THE MEETING TO
5	ORDER PLEASE. WOULD YOU CONDUCT A ROLL CALL,
6	MELISSA.
7	MS. KING: ROBERT PRICE. FLOYD BLOOM.
8	DR. BLOOM: HERE.
9	MS. KING: MARCY FEIT. MICHAEL GOLDBERG.
10	CHAIRMAN GOLDBERG: HERE.
11	MS. KING: BOB KLEIN.
12	CHAIRMAN KLEIN: HERE.
13	MS. KING: TED LOVE. PHIL PIZZO. DUANE
14	ROTH. DAVID SERRANO-SEWELL. JEFF SHEEHY.
15	MR. SHEEHY: HERE.
16	MS. KING: OSWALD STEWARD.
17	DR. STEWARD: HERE.
18	MS. KING: ART TORRES.
19	AS I NOTED, I KNOW SENATOR TORRES WILL BE
20	JOINING US MOMENTARILY.
21	CHAIRMAN GOLDBERG: LET'S PROCEED. I'VE
22	ASKED JOHN ROBSON TO WALK US THROUGH AN OVERVIEW OF
23	THE PROPOSED 2011-2012 BUDGET, IN PARTICULAR TO
24	ADDRESS WHERE WE APPEAR TO BE COMING OUT ON THE
25	2010-2011 BUDGET AND UNDERSTAND THE BASE FROM WHICH
	3

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	WE'RE BEING PROJECTED.
2	MS. KING: MICHAEL, I THINK YOU MIGHT BE
3	CUTTING OUT JUST A LITTLE BIT. IT MIGHT BE BETTER
4	IF YOU WERE CLOSER TO THE PHONE.
5	CHAIRMAN GOLDBERG: WELL, I WOULD HAVE TO
6	SWALLOW IT. IS THAT ANY BETTER?
7	MS. KING: THANK YOU.
8	CHAIRMAN GOLDBERG: SHALL I REPEAT MYSELF?
9	MS. KING: MAYBE JUST BRIEFLY, IF YOU
10	WOULD. AND WE'VE JUST BEEN JOINED BY MARGARET
11	FERGUSON AS WELL, WHO I KNOW WILL BE MAKING PART OF
12	THIS PRESENTATION. SO IT'S PERFECT TIMING, MICHAEL.
13	IF YOU COULD JUST GO BACK OVER WHAT YOU JUST SAID
14	FOR EVERYBODY'S BENEFIT, INCLUDING MARGARET'S, THAT
15	WOULD BE GREAT.
16	CHAIRMAN GOLDBERG: THE GAME PLAN FOR THIS
17	AGENDA ITEM IS FOR JOHN ROBSON TO PRESENT THE
18	POWERPOINT SLIDES THAT HAVE BEEN CIRCULATED TO ALL
19	THE SITES. IT WAS BASED ON A REVIEW THAT JOHN,
20	MARGARET, AND CHILA HAD WITH MARCY FEIT AND MYSELF
21	SERIALLY OVER THE LAST SEVERAL MONTHS AND
22	REPRESENTS, I THINK, OUR COLLECTIVE VIEW OF THE
23	STATE OF THE BUDGET FOR 2011-2012. THE GOAL OF THIS
24	MEETING IS TO SOLICIT COMMENTS FROM MEMBERS OF THE
25	SUBCOMMITTEE AND TO SEE IF WE CAN ARRIVE AT A

1	CONSENSUS POSITION FOR REPRESENTATION TO THE BOARD
2	AT OUR UPCOMING ICOC MEETING IN LOS ANGELES.
3	WITH THAT, LET ME TURN IT OVER TO JOHN
4	ROBSON.
5	DR. ROBSON: THANK YOU, MICHAEL AND
6	MEMBERS OF THE SUBCOMMITTEE. LET ME JUST SORT OF
7	I'M GOING TO WORK OFF OF THE POWERPOINTS THAT I SENT
8	TO YOU. IF I SAY NEXT SLIDE, WHAT I MEAN IS NEXT
9	PAGE.
10	ANYWAY, THIS PROCESS STARTED IN DECEMBER.
11	I THINK AT THE LAST BOARD MEETING, I GAVE A BIT OF
12	AN OVERVIEW OF THE TIMELINE WE FOLLOWED. WE GOT A
13	FIRST BUDGET PUT TOGETHER, A FIRST DRAFT OF IT, AT
14	THE END OF JANUARY. THAT BUDGET WAS ABOUT A LITTLE
15	BIT OVER \$20 MILLION. ABOUT THE SAME TIME WE GOT
16	INFORMATION FROM THE GOVERNOR'S OFFICE THAT THERE
17	WAS EXPECTED TO BE SOME SEVERE RESTRICTIONS ON
18	BUDGETS. SO WE WENT THROUGH A FAIRLY SEVERE CUT.
19	WE TOOK MORE THAN 20 PERCENT OFF THAT BUDGET, AND
20	THEN SENT THE ITEMS BACK TO THE INDIVIDUAL UNITS
21	REQUESTING ADDITIONAL JUSTIFICATION FOR ANYTHING
22	THEY WANTED REINSERTED IN THE BUDGET. WE ENDED UP
23	WITH A BUDGET, AFTER A FEW ITERATIONS, THAT YOU SEE
24	TODAY, WHICH IS AN INCREASE OF ABOUT 16 PERCENT OVER
25	WHAT WAS APPROVED LAST YEAR AT A TOTAL OF ABOUT

1	\$18.5 MILLION.
2	BUT WE'RE ALWAYS ASKED TO GO TO THE I
3	GUESS IT'S THE FIRST SLIDE AFTER THE COVER SLIDE.
4	WE'RE ALWAYS ASKED HOW DOES THIS BUDGET COMPARE NOT
5	JUST WITH WHAT WAS APPROVED LAST YEAR, BUT WHAT WE
6	ACTUALLY EXPECT TO EXPEND. SO THAT ONE TABLE SHOWS
7	YOU A LITTLE BIT OF HISTORY. FROM THE LAST TWO
8	YEARS, IN FISCAL YEARS 2009-10, WE HAD AN APPROVED
9	BUDGET OF 12.9 MILLION AND WE SPENT ABOUT 12.3. WE
10	WERE ABOUT 4.7 PERCENT UNDER.
11	THIS YEAR'S APPROVED BUDGET WAS 16
12	MILLION, AND WE ANTICIPATE WE PROJECT THAT WE AT
13	THE END OF JUNE WILL HAVE EXPENDED 15.2 MILLION, SO
14	WE'LL BE ABOUT THE SAME, ABOUT 5 PERCENT UNDER
15	BUDGET. AND I THOUGHT IT MIGHT BE OF SOME USE TO
16	YOU TO SEE A BIT OF HISTORY ON THIS.
17	IF YOU GO TO THE NEXT SLIDE, THE GRAPH,
18	THE TABLE GRAPH THE BAR GRAPHS SHOW THE HISTORY
19	OF OUR APPROVED BUDGET VERSUS OUR ACTUAL
20	EXPENDITURES DATING BACK TO FISCAL YEAR 2006-7. AND
21	YOU CAN SEE IN THOSE FIRST THREE YEARS WE WERE
22	GENERALLY QUITE A BIT UNDER WHAT WAS APPROVED. BUT,
23	AGAIN, THESE WERE PERIODS OF REALLY ACTIVE GROWTH IN
24	THE INSTITUTION. AND YOU WILL SEE IN THE LAST TWO
25	YEARS WE'VE BEEN MUCH BETTER. WE'VE COME MUCH

1	CLOSER OUR ACTUAL REQUESTS HAVE BEEN MUCH CLOSER
2	TO WHAT WE'VE EXPENDED, BEING ABOUT 5 PERCENT UNDER.
3	NOW, I'D JUST KIND OF LIKE TO GO THROUGH
4	QUICKLY SOME OF THE THINGS THAT DROVE THIS BUDGET.
5	WHY HAS IT INCREASED? AND THEN DISCUSS REALLY FROM
6	AN OVERVIEW WHAT THE CAUSES OF THE INCREASE, WHAT
7	THE PARTICULARS ARE.
8	SO IF YOU GO TO THE NEXT PAGE, YOU WILL
9	SEE A TABLE ON CIRM GROWTH WITH PR'S AND PAR'S,
10	PAYMENTS, AND CO-FUNDING. SO THE PR'S AND PAR'S,
11	THAT'S REFERRING TO PROGRESS REPORTS AND PRIOR
12	APPROVAL REQUESTS. PROGRESS REPORTS ARE THE
13	PERIODIC REPORTS THAT WE GET FROM OUR GRANTEES.
14	PRIOR APPROVAL REQUESTS ARE REQUESTS FROM THE
15	GRANTEES OF APPROVED GRANTS TO MAKE CHANGES IN THOSE
16	GRANTS. THOSE COULD BE BUDGETARY CHANGES; THEY
17	COULD BE PROGRAMMATIC CHANGES. AND YOU WILL SEE
18	THAT THESE THINGS REALLY CONSTITUTE A GOOD
19	PROPORTION OF THE WORKLOAD FOR BOTH THE GRANTS
20	MANAGEMENT OFFICE AND THE SCIENCE OFFICE. AND YOU
21	WILL SEE FROM FISCAL YEAR '09-'10 TO '10-'11,
22	THERE'S BEEN OVER 20-PERCENT INCREASE IN THE NUMBER
23	OF PRIOR APPROVAL REQUESTS AND PROGRESS REPORTS.
24	PAYMENTS ARE THE PAYMENTS THAT WE MAKE TO
25	OUR GRANTEES. THOSE ARE HANDLED THROUGH THE GRANTS

1	MANAGEMENT OFFICE AND THEN THROUGH THE FINANCE
2	OFFICE. EACH ONE OF THOSE HAS TO BE HANDLED
3	INDIVIDUALLY. AND THE GENERAL SERVICE, AND YOU CAN
4	SEE THERE'S AN INCREASE OF ALMOST 50 PERCENT IN
5	THOSE IN THE PAST YEAR.
6	AND THEN, FINALLY, WE HAVE GRANTS WITH
7	CO-FUNDING PARTNERS. THESE ARE OUR CO-FUNDERS FROM
8	AROUND THE WORLD. IN FISCAL YEAR '09-'10, WE HAD
9	FOUR OF THOSE. NOW WE HAVE 15. THOSE NUMBERS ARE
10	NOT VERY BIG, BUT THOSE GRANTS ARE A LOT MORE WORK.
11	TALKING TO THE MEMBERS OF THE SCIENCE OFFICE AND THE
12	GRANTS MANAGEMENT OFFICE, THEY SAY THAT THEY'RE ONE
13	AND A HALF TO TWO TIMES AS MUCH WORK AS A TYPICAL
14	GRANT TO JUST A SINGLE PI IN CALIFORNIA.
15	SO THOSE ARE SOME OF THE DRIVERS OF OUR
16	INCREASE IN OUR WORKLOAD. WE ALSO HAVE ANTICIPATED
17	INCREASES IN WORK BECAUSE WE NOW HAVE CLINICAL
18	PROGRAMS THAT ARE GETTING STARTED. AND WE HAVE
19	INCREASED OVERSIGHT THAT'S GOING TO BE REQUIRED OF
20	THOSE PROGRAMS. SO WE'VE HIRED ELLEN FEIGAL IS NOW
21	HERE AS THE VICE PRESIDENT FOR RESEARCH AND
22	DEVELOPMENT, AND SHE'S PUTTING TOGETHER REVIEW
23	PANELS AND PLANNING TO HIRE STAFF TO MANAGE THIS
24	PROCESS OF KEEPING TRACK OF OUR CLINICAL PROGRAMS.
25	WE ALSO FEEL IT'S GOING TO BE IMPORTANT TO

1	MAKE SURE THAT THERE'S A CLEAR REGULATORY PATH FOR
2	OUR GRANTEES AND THAT THERE WILL BE FOLLOW-ON
3	FUNDING. AND SO THIS GRANT ALSO THIS BUDGET ALSO
4	INCLUDES PROVISIONS FOR THOSE. THOSE ARE COMING
5	PRIMARILY FROM ELONA BAUM OUT OF THE PRESIDENT'S
6	OFFICE SO THAT OUR GRANTEES WILL BE READY TO MOVE ON
7	TOWARDS THE CLINIC WHEN WE GET THERE.
8	SO WE GO TO THE NEXT PAGE SHOWS A
9	COMPARISON BETWEEN THE FISCAL YEAR '10-'11 BUDGET
10	AND '11-'12 BUDGET BOTH ON THE APPROVED, WHAT WAS
11	APPROVED LAST YEAR, VERSUS WHAT WE'RE REQUESTING, A
12	\$2.5 MILLION INCREASE. AND IF YOU'D LIKE TO SEE
13	WHAT IT IS COMPARED TO EXPENDED, IT'S A \$3.3 MILLION
14	INCREASE COMPARED TO WHAT WE PROJECTED WE'RE GOING
15	TO SPEND DURING THIS FISCAL YEAR.
16	LET'S GO ON TO THE NEXT SLIDE, WHICH I'D
17	LIKE TO GET INTO WHAT ARE THE MAIN DRIVERS OF THIS
18	INCREASE. WHERE DID THIS \$2.5 MILLION INCREASE COME
19	FROM? MOST OF IT COMES FROM SALARIES AND FRINGE
20	BENEFITS. AS YOU KNOW, THE ALQUIST BILL LIFTED
21	CIRM'S 50-EMPLOYEE CAP. AND SO WE ARE NOW FREE TO
22	HIRE AS MANY EMPLOYEES AS WE WANT AS LONG AS WE STAY
23	WITHIN OUR 6-PERCENT FUNDING CAP.
24	AND SO THIS BUDGET HAS AN INCREASE OF SIX
25	INDIVIDUALS. THERE'S ACTUALLY IT MAY NOT BE THAT

1	OBVIOUS TO YOU WHEN YOU LOOK AT THE TABLES WHICH ARE
2	THE NEW ONES BECAUSE THERE HAVE BEEN SOME POSITIONS
3	THAT HAVE BEEN RECATEGORIZED, MOVED FROM ONE
4	REPORTING UNIT TO ANOTHER, AND A COUPLE POSITIONS
5	HAVE BEEN ELIMINATED, BUT THE NET INCREASE IS SIX.
6	SO WE ANTICIPATE GOING FROM 50 TO 56. THAT INCREASE
7	WILL AMOUNT TO A MILLION AND A HALF DOLLARS. IT
8	INCLUDES ALL THE SALARIES FOR THOSE INDIVIDUALS PLUS
9	ABOUT \$500,000 FOR RETIREMENT, HEALTH BENEFITS, AND
10	MERIT INCREASES FOR THE STAFF.
11	MOVING ON TO THE NEXT CATEGORY WHERE
12	THERE'S A FAIRLY BIG CHANGE, THAT'S IN EXTERNAL
13	CONTRACTS. I THINK IF YOU LOOK THROUGH THE BUDGET,
14	WHAT YOU WILL SEE IS MOST OF THIS INCREASE IS
15	RELATED TO AUDITS. IN THE LAST FISCAL YEAR, WE HAD
16	THE EXTERNAL REVIEW. WE HAD ABOUT \$180,000 BUDGETED
17	FOR THAT. THIS YEAR THAT ITEM IS NOT THERE, SO WE
18	CAN REMOVE THAT FROM THE REQUEST FOR THIS YEAR.
19	HOWEVER, WE HAVE TWO ADDITIONAL AUDITS THAT ARE IN
20	THE BUDGET. ONE IS FOR THE ONE FROM THE ALQUIST
21	BILL. THAT'S THE PERFORMANCE AUDIT AT \$250,000, AND
22	THEN THERE'S AN INSTITUTE OF MEDICINE AUDIT THAT IS
23	BEING ORGANIZED BY THE OFFICE OF THE CHAIR. AND
24	THAT'S BUDGETED AT \$400,000 FOR THIS YEAR. THERE
25	WOULD BE AN ADDITIONAL PAYMENT THAT WOULD BE IN THE

1	NEXT FISCAL YEAR.
2	SO IF YOU JUST SUM UP THOSE THREE AUDITS,
3	YOU WILL SEE THAT THAT IS A NET INCREASE OF \$470,000
4	JUST FOR AUDITS, WHICH IS MORE THAN THE TOTAL
5	INCREASE FOR CONTRACTS. SO OTHER BASE CONTRACTS ON
6	AVERAGE HAVE BEEN REDUCED A BIT.
7	AND IF WE GO TO THE NEXT PAGE, WE'LL TALK
8	ABOUT SCIENCE MEETINGS. THERE'S BEEN A SUBSTANTIAL
9	INCREASE THERE, 338,000. AND THAT CAN BE ATTRIBUTED
10	MOSTLY TO THE FACT THAT WE'RE HAVING A GRANTEE
11	MEETING THIS YEAR. WE DON'T HAVE A GRANTEE MEETING
12	EVERY YEAR. WE'VE BEEN HAVING IT ABOUT EVERY 18
13	MONTHS. SO THERE WAS NO GRANT MEETING BUDGETED FOR
14	THIS PAST FISCAL YEAR, BUT THERE WILL BE FOR THIS
15	COMING FISCAL YEAR, AND THAT AMOUNTS TO \$262,000.
16	THE OTHER ITEM THAT'S NEW HERE IS \$125,000 TO SEND
17	TRAINEES AND PATIENT ADVOCATES TO THE WORLD STEM
18	CELL CONFERENCE NEXT FALL. SO THOSE TWO THINGS
19	TOGETHER, AGAIN, THEY MORE THAN EQUAL THE TOTAL
20	INCREASE IN THAT CATEGORY. SO IN OTHER INSTANCES IN
21	THIS CATEGORY, THE REQUESTS HAVE BEEN REDUCED.
22	SO IF WE GO TO THE LAST PAGE, THAT'S MY
23	SIGNAL REALLY TO STOP TALKING AND OPEN THIS UP TO
24	QUESTIONS. MAYBE I'LL JUST RUN DOWN SOME OF THE
25	OTHER CATEGORIES THAT I DIDN'T MENTION. WE'VE GONE

1	THROUGH SALARIES AND BENEFITS, BUT IF YOU JUST LOOK
2	AT THE RIGHT, THE LAST TWO COLUMNS ON THE RIGHT, WE
3	GO DOWN THERE. INTERAGENCY AGREEMENTS, THESE ARE
4	AGREEMENTS WE HAVE WITH DIFFERENT STATE AGENCIES TO
5	HANDLE DIFFERENT ASPECTS MOSTLY AROUND FINANCE.
6	THESE AGENCIES WORK ON A COST RECOVERY BASIS, AND
7	THIS INCREASE JUST MERELY REFLECTS THE INCREASE IN
8	THE WORKLOAD THAT WE HAVE REQUIRED OF THEM.
9	MOVING ON DOWN, WE CAN SKIP CONTRACTS AND
10	GO TO ICOC MEETINGS. THAT INCREASE IS \$27,000.
11	THAT'S A FIGURE THAT WAS PROVIDED TO US BY THE
12	CHAIR'S OFFICE. WE GO DOWN AND SKIP OVER SCIENCE
13	MEETINGS AND GO TO GRANTS WORKING GROUPS. THERE'S
14	AN INCREASE OF 4 PERCENT THERE. WE'VE ACTUALLY
15	TRIMMED BACK SOMEWHAT ON THOSE BECAUSE WE ARE
16	INCLUDING IN THAT NOW THIS CLINICAL REVIEW PANEL.
17	SO SOME OF THOSE MEETINGS ARE INCORPORATED IN HERE,
18	AND THOSE WILL BE FAIRLY EXPENSIVE. SO THAT
19	ACCOUNTS FOR THE INCREASE THERE. STANDARDS WORKING
20	GROUP THERE'S NO INCREASE. TRAVEL, THERE'S A SMALL
21	DECREASE. FURNITURE AND EQUIPMENT, NO INCREASE.
22	INFORMATION TECHNOLOGY, THERE'S AN
23	INCREASE OF 7 PERCENT OR \$80,000. MOST OF THAT,
24	ABOUT \$80,000 OF THAT, IS JUST DUE TO A
25	RECATEGORIZATION. WE TOOK A COUPLE OF ITEMS THAT IN

1	THE LAST BUDGET THAT WERE INCLUDED AS COMMUNICATIONS
2	IN THE OFFICE OF ADMINISTRATION, AND WE'VE MOVED
3	THOSE BECAUSE THEY WERE RELATED TO THE WEBSITE.
4	WE'VE MOVED THOSE INTO INFORMATION TECHNOLOGY, SO
5	THAT'S THE REASON FOR THAT SMALL INCREASE THERE.
6	AND THEN OUR OTHER OPERATIONS HAVE BEEN
7	REDUCED BY 44,000. I'LL STOP THERE AND LEAVE IT TO
8	PEOPLE FOR QUESTIONS.
9	CHAIRMAN GOLDBERG: THANK YOU VERY MUCH,
10	JOHN. BEFORE I OPEN IT UP TO QUESTIONS FROM THE
11	SITES, I'D LIKE TO MAKE A FEW COMMENTS, AND THEN
12	CHAIRMAN KLEIN WOULD LIKE TO MAKE A FEW COMMENTS AS
13	WELL.
14	THE FIRST IS THAT I THINK I CAN REPRESENT
15	ALL OF US ON THE ICOC SAYING THAT WE'RE EXTREMELY
16	SENSITIVE, AS I KNOW THE CIRM STAFF HAS BEEN IN THE
17	PREPARATION OF THIS BUDGET, TO THE STATE AND EVEN
18	FEDERAL FISCAL CONDITION. AND THE DIRECTION THAT
19	WE'VE PROVIDED TO STAFF IS TO DEFER WHEREVER
20	POSSIBLE NONMISSION CRITICAL SPENDING AND
21	INVESTMENTS. THEY HAVE CYCLED BACK AND DONE, I
22	THINK, A VERY EFFECTIVE JOB OF PROVIDING A BUDGET
23	THAT LARGELY ACCOMPLISHES THAT.
24	IF YOU FUNDAMENTALLY LOOK AT THE
25	YEAR-OVER-YEAR SPEND IN EXISTING EXPENSE CATEGORIES,

1	IT'S VERY CLOSE TO FLAT. AND THEN THE INCREASES ARE
2	ATTRIBUTABLE PRINCIPALLY TO ACTIVITY-RELATED VOLUME
3	WHICH IS ENTIRELY EXPECTED. SO IN THAT REGARD I
4	THINK THE STAFF SHOULD BE COMPLIMENTED FOR THE WORK
5	THEY'VE DONE AT THE DEPARTMENT LEVEL AND ACROSS ALL
6	ASPECTS OF THE AGENCY.
7	IN REGARD TO SEVERAL OF THE MAJOR ITEMS
8	THAT STAND OUT AS INCREASES THAT MAY NOT BE
9	CONSIDERED TO BE ORDINARY AND NECESSARY AS ONE-TIME
10	INVESTMENTS OR EXPENDITURES, I THINK THAT'S KIND OF
11	WHERE WE SHOULD FOCUS OUR ATTENTION AND WHERE THE
12	BOARD'S ATTENTION SHOULD BE FOCUSED.
13	IN THAT REGARD, I THINK IT WOULD BE
14	HELPFUL FOR EVERYONE TO HEAR FROM CHAIRMAN KLEIN
15	ABOUT HOW SOME OF THOSE ACTIVITIES MAY BE FUNDED IN
16	SUCH A WAY THAT IT WOULD NOT DIRECTLY IMPACT THE
17	AGENCY'S AVAILABLE FUNDING FROM BOND PROCEEDS. WITH
18	THAT, I'D LIKE TO TURN IT OVER TO CHAIRMAN KLEIN.
19	CHAIRMAN KLEIN: THANK YOU, MICHAEL. SO
20	JUST FOR SOME VERY QUICK OVERVIEW POINTS BEFORE
21	QUESTIONS. IF YOU LOOK AT THE TOTAL INCREASE,
22	THERE'S 525,000 OF IT THAT RELATES TO EITHER THE IOM
23	STUDY OF \$400,000 ITEM OR THE WORLD STEM CELL
24	CONFERENCE BEING A HUNDRED TWENTY-FIVE. BOTH OF
25	THOSE ITEMS ARE FUNDED OUT OF DONOR FOUNDS, NOT OUT

1	OF FUNDS RAISED BY TAXES ON THE CITIZENS OF
2	CALIFORNIA.
3	THOSE DONOR FUNDS WERE RAISED OVER SIX
4	YEARS AGO WITH A REPRESENTATION THAT THEY WOULD BE
5	USED TO ADVANCE THE MISSION AND BE USED RELATIVELY
6	RAPIDLY AS OPPORTUNITIES OCCURRED. WE HAVE BEEN
7	SUCCESSFUL PREVIOUSLY IN GETTING OTHER PARTIES TO
8	PAY FOR SOME OF THESE ACTIVITIES GIVEN TIGHT
9	BUDGETARY PROBLEMS AFFECTING NOT ONLY THE PUBLIC
10	GOVERNMENTAL SECTOR, BUT THE NONPROFIT SECTOR. SOME
11	OF THOSE ACTIVITIES CAN'T BE PAID BY THE NONPROFIT
12	SECTOR, AND WE'RE PAYING IT WITH THE DONOR FUNDS
13	THAT WERE RAISED FOR THAT VERY PURPOSE. SO THAT'S
14	525,000 OR ABOUT 3.8 PERCENT OF THE INCREASE.
15	ADDITIONALLY, IT'S IMPORTANT TO UNDERSTAND
16	THAT THERE IS THIS \$250,000 STATE MANDATED AUDIT,
17	WHICH IS ANOTHER 1.3 PERCENT OF THE INCREASE
18	EXCUSE ME WHICH IS ANOTHER 1.6 PERCENT OF THE
19	INCREASE. AND IN ADDITION, WHEN WE REALLY LOOK AT
20	WHERE THE FUNDS ARE GOING, THE FUNDS ARE EFFECTIVELY
21	GOING INTO SIX POSITIONS, FOUR OF WHICH ARE IN THE
22	SCIENCE OFFICE, ONE IS A PUBLIC COMMUNICATIONS
23	DIRECTOR SPECIFICALLY MANDATED BY THE BOARD,
24	RECOGNIZING THAT'S GOING TO BE VITAL TO HAVE GOOD
25	COMMUNICATIONS DURING THIS PERIOD AS WE ENTER INTO

1	CLINICAL TRIALS FOR THE LEAD-UP TO CLINICAL TRIALS
2	WITH CELLULAR THERAPIES.
3	IN THE PERSONNEL AREA FOR THE SCIENCE
4	OFFICE, WE'VE HAD EXTENSIVE DISCUSSIONS WITH DR.
5	TROUNSON, DR. ROBSON, AND THE SCIENTIFIC STAFF, AND
6	I ACTUALLY THINK THEY'VE REALLY CUT DOWN THE STAFF
7	TO THE ABSOLUTE MINIMUM INCREASE WHEN WE'RE DEALING
8	WITH THE FACT WE HAVE A SCIENTIFIC ADVISORY
9	COMMITTEE THAT'S GOING TO BE COMING ON ON CLINICAL
10	TRIALS, AND THE COMPLEXITY AND THE MATURITY OF OUR
11	GRANTS HAS MOVED DOWNSTREAM TO WHERE THERE'S REALLY
12	SUBSTANTIAL MILESTONES, A LOT OF INTERACTION THAT'S
13	NECESSARY TO WORK WITH THEM WHETHER IT'S EARLY
14	TRANSLATION OR DISEASE TEAMS OR OTHER CATEGORIES OF
15	THAT TYPE.
16	SO IF YOU REALLY IF YOU TAKE OUT 9.3
17	PERCENT FOR THE SIX PERSONNEL MEMBERS, YOU TAKE OUT
18	THE DONOR FUNDS, AND YOU TAKE OUT THE REQUIREMENT OF
19	\$250,000 FOR A LEGISLATIVE MANDATED AUDIT, YOU'RE AT
20	A 1.3-PERCENT OVERALL INCREASE. I THINK THAT
21	REFLECTS THE REAL DISCIPLINE HERE, EFFECTIVELY
22	CONTROLLABLE COSTS THAT ARE FUNDED WITH STATE
23	TAXPAYER RAISED DOLLARS REPRESENT A 1.3 PERCENT
24	INCREASE.
25	MR. TORRES: BOB, IF WE CAN CHANGE THAT
	16

1	PAGE, THAT SLIDE, TO REFLECT THOSE ISSUES BECAUSE
2	ONCE THIS DOCUMENT BECOMES PUBLIC, THEN PEOPLE
3	ASSUME THE 400,000 AND THE \$250,000, IT SHOULD SAY
4	PERFORMANCE AUDIT MANDATED BY THE CALIFORNIA
5	LEGISLATURE, \$250,000. THE IOM AUDIT, 400,000,
6	COMING FROM DONOR FUNDS, NOT TAXPAYER FUNDS. SO WE
7	NEED TO MAKE SURE THAT IT'S AS SIMPLISTIC AS
8	POSSIBLE THAT GETS THE MESSAGE OUT THERE AS TO THE
9	ORIGIN OF THOSE NUMBERS.
10	CHAIRMAN KLEIN: I AGREE COMPLETELY. I'VE
11	HAD SOME PRIOR EXTENSIVE DISCUSSIONS WITH JOHN
12	ROBSON. I THINK IT'S HIS INTENT AFTER THIS MEETING
13	TO DO SO. I THINK HE WAS CAUGHT SHORT ON TIME TO
14	GET IT DONE FOR THIS MEETING.
15	MR. TORRES: HE'S NODDING.
16	CHAIRMAN GOLDBERG: THANK YOU, ART TORRES.
17	JOHN ROBSON, JUST TO BE SURE THAT FOR THE
18	MATERIALS THAT WILL BE PROVIDED TO THE ICOC, THE
19	UPCOMING MEETING, THE CHANGES THAT WERE JUST
20	DISCUSSED WILL BE MADE.
21	DR. ROBSON: ABSOLUTELY.
22	CHAIRMAN GOLDBERG: THANK YOU. I'D LIKE
23	TO CIRCULATE AROUND THE SITES.
24	MR. TORRES: WAIT. SO FINAL QUESTION.
25	WHEN WE SPEAK TO THE LEGISLATURE, OR I SPEAK TO THE

1	LEGISLATURE, WE'VE ONLY HAD A 1.3-PERCENT INCREASE,
2	CORRECT?
3	CHAIRMAN KLEIN: SEPARATE FROM THE SIX
4	PERSONNEL MEMBERS SPECIFICALLY AUTHORIZED BY THE NEW
5	LEGISLATION, THAT THE LEGISLATURE PASSED, AND OF
6	THOSE, FOUR ARE SCIENCE OFFICERS DEALING WITH
7	OVERSIGHT BY THE ADVISORY COMMITTEE AND WORK ON
8	PRECLINICAL OR CLINICAL LEVEL SCIENTIFIC CHALLENGES.
9	CHAIRMAN GOLDBERG: ART, COULD I PERHAPS
10	ASK YOU TO WORK WITH JOHN ROBSON TO CONSTRUCT A KIND
11	OF ONE-PAGE SUMMARY OF THE PROPOSED BUDGET THAT
12	WOULD INTEGRATE ALL OF THE COMMENTS THAT HAVE JUST
13	BEEN DISCUSSED SO THAT IT'S A BASIS FOR TALKING
14	POINTS NOT ONLY FOR YOU TO THE LEGISLATURE, BUT FOR
15	EACH OF US AND TO THE PUBLIC AT LARGE.
16	MR. TORRES: AND ALSO TO DON, WHO I'M SURE
17	WILL ISSUE A PRESS RELEASE AT THE TIME OF THE BOARD
18	MEETING.
19	CHAIRMAN GOLDBERG: YEAH. OR PERHAPS EVEN
20	TODAY.
21	MR. TORRES: OKAY.
22	CHAIRMAN GOLDBERG: BUT THANK YOU FOR
23	THOSE COMMENTS. ARE YOU AT CIRM, ART, OR ARE YOU AT
24	ANOTHER SITE?
25	MR. TORRES: SAN FRANCISCO. ARE THERE

	DARRISTERS REPORTING SERVICE
1	OTHER COMMENTS FROM YOUR SITE?
2	MR. TORRES: ANY OTHER COMMENTS?
3	MS. KING: MICHAEL, YOU'RE JUST LOOKING
4	FOR COMMENTS FROM BOARD MEMBERS RIGHT NOW? ART IS
5	THE ONLY BOARD MEMBER THAT'S HERE, SO IF YOU'D LIKE,
6	I CAN CALL OUT THE SITES IF THAT WOULD BE HELPFUL.
7	CHAIRMAN GOLDBERG: YEAH, PLEASE.
8	MS. KING: SURE. DO WE HAVE ANY COMMENTS
9	FROM ROANOKE STREET HERE IN SAN FRANCISCO?
10	MR. SHEEHY: NO COMMENTS.
11	MS. KING: MICHAEL, OVER TO YOUR SITE.
12	YOU ARE AT KLEIN FINANCIAL WITH BOB, CORRECT?
13	CHAIRMAN GOLDBERG: NO COMMENTS.
14	MS. KINGS: ANY COMMENTS, BOB?
15	CHAIRMAN KLEIN: NO ADDITIONAL COMMENTS.
16	THANK YOU.
17	MS. KING: DR. STEWARD AT UC IRVINE, ANY
18	COMMENTS?
19	DR. STEWARD: NO ADDITIONAL COMMENTS.
20	MS. KING: DR. BLOOM AT THE SCRIPPS
21	RESEARCH INSTITUTE, ANY COMMENTS?
22	DR. BLOOM: NO COMMENTS.
23	MS. KING: IS THERE ANYBODY THAT WE'VE
24	MISSED? WE CALLED JEFF SHEEHY'S LOCATION. SO IS
25	THERE ANYBODY ON THE LINE THAT WE MISSED WHO MAY
	19
	1

19

1	HAVE JOINED THE CALL SINCE THE ROLL CALL? LIKE
2	MAYBE WHO JUST BEEPED IN?
3	MS. FEIT: MARCY FEIT.
4	MS. KING: YOU PROBABLY DON'T HAVE ANY
5	COMMENTS. WELL, YOU MIGHT BECAUSE YOU HAD THE
6	DOCUMENTS FOR A FEW DAYS. WHAT WE'RE DOING RIGHT
7	NOW IS GETTING COMMENTS FROM THE SUBCOMMITTEE
8	MEMBERS ON THE BUDGET FOLLOWING A PRESENTATION BY
9	JOHN ROBSON. SO IF YOU HAVE ANY COMMENTS BASED ON
10	YOUR PRIOR REVIEW OF THE DOCUMENTS, NOW WOULD BE A
11	GOOD TIME, OR MAYBE YOU COULD DEFER THOSE UNTIL
12	AFTER WE CHECK FOR PUBLIC COMMENTS, SO YOU HAVE A
13	MOMENT TO THINK ABOUT IT.
14	CHAIRMAN KLEIN: MARCY, THIS IS BOB KLEIN.
15	JUST TO RESUMMARIZE WHAT I JUST WENT THROUGH FOR THE
16	COMMITTEE, WHEN YOU TAKE AND ANALYZE THE COMPONENTS
17	OF THE INCREASE, 525,000 IS NOT FUNDED BY STATE
18	TAXPAYER DOLLARS. IT'S FUNDED BY DONOR FUNDS FROM
19	MONEY SPECIFICALLY RAISED FOR CONFERENCES AND
20	SPECIAL STUDIES. THAT HAPPENS TO BE 3.8 PERCENT OF
21	THE INCREASE. AN ADDITIONAL 1.6 PERCENT OF THE
22	INCREASE COMES FROM THE LEGISLATURE'S \$250,000
23	MANDATED AUDIT, MAKING 5.4 PERCENT OF THE INCREASE
24	COMBINED WITH THE DONOR FUNDS.
25	AND WHEN YOU LOOK AT THE ACTUAL INCREASE,
	20

1	IT'S SIX PERSONNEL MEMBERS, FOUR WHICH ARE SCIENCE
2	OFFICERS THAT ARE DEEPLY INVOLVED AND REQUIRED WITH
3	THE FACT THAT WE HAVE MORE MATURE GRANTS THAT ARE IN
4	PRECLINICAL OR CLINICAL PHASES, WE HAVE A SCIENTIFIC
5	ADVISORY COMMITTEE THAT NEEDS TO BE ADDED FOR
6	OVERSIGHT BECAUSE IT'S SO CRITICAL TO HAVE PROPER
7	FOLLOW-THROUGH ON THIS PRECLINICAL AND CLINICAL
8	PHASE. AND ONE OF THE OTHERS IS THE DIRECTOR OF
9	PUBLIC COMMUNICATIONS THAT THE BOARD SPECIFICALLY
10	DIRECTED FOR THE CHAIR'S OFFICE TO REALLY
11	COMMUNICATE WITH THE PUBLIC AND THE LEGISLATURE
12	ABOUT THE MILESTONES OF PROGRESS IN THE STEM CELL
13	RESEARCH AND THERAPY AREA. AND ONE IS AN ADDITION
14	TO THE OFFICE OF THE PRESIDENT.
15	SO VERY SMALL INCREASES SPECIFICALLY
16	AUTHORIZED LAST YEAR BY THE LEGISLATURE TO ALLOW US
17	TO GO FROM 50 PERSONS TO 56. BUT WHEN YOU SUBTRACT
18	OUT JUST PERSONNEL AND THE NONSTATE TAXPAYER FUNDED
19	ITEMS ALONG WITH THE LEGISLATIVE AUDIT ITEMS, YOU
20	HAVE A NET INCREASE OF 1.3 PERCENT.
21	MS. FEIT: THANK YOU. I DON'T HAVE ANY
22	ADDITIONAL COMMENTS. I THINK I'VE SPENT TIME
23	TALKING WITH OTHERS ABOUT THIS BUDGET, AND I'VE
24	LOOKED AT THE BUDGET MYSELF. AND I THINK THE
25	JUSTIFICATION FOR THE CHANGES ARE MORE THAN

1	WARRANTED WITH THE AMOUNT OF WORK THAT CIRM HAS TO
2	PRODUCE TO MEET ITS COMMITMENTS. WE CONSISTENTLY
3	YEAR AFTER YEAR HAVE BEEN UNDER BUDGET, AND I THINK
4	HAVE BEEN REALLY MORE THAN PRUDENT ABOUT HOW WE'VE
5	UTILIZED OUR FUNDS IN THE PAST. AND I ANTICIPATE
6	THAT WILL HAPPEN GOING FORWARD.
7	MR. TORRES: ANY OTHER BOARD MEMBERS?
8	CHAIRMAN GOLDBERG: THIS IS MICHAEL
9	GOLDBERG ON BEHALF OF DUANE ROTH, WHO WON'T BE ABLE
10	TO JOIN THE CALL UNTIL THE NEXT HOUR. HE HAS STRONG
11	OPPOSITION TO THE USE OF TAXPAYER MONEY HE MAY
12	NOT HAVE UNDERSTOOD THE USE OF DONOR FUNDS
13	TAXPAYER MONEY FOR THE IOM STUDY. HE FEELS THAT
14	HAVING JUST HAD AN EXTERNAL REVIEW BY A TEAM OF
15	EXPERTS COMPLETED WHICH DOCUMENTED THAT CIRM IS
16	MEETING ITS GOALS AND HAVING THE IMPACT INTENDED BY
17	PROP 71, HE DOESN'T SEE HOW AN ADDITIONAL STUDY
18	WOULD RESULT IN ANY INCREMENTAL BENEFIT TO CIRM AT
19	THIS TIME. AND DOESN'T FEEL THAT WE SHOULD BE
20	SPENDING MONEY ON NONCRITICAL ITEMS. THEREFORE,
21	HE'S OPPOSED TO INCLUDING THIS ITEM IN THE BUDGET
22	FOR NEXT YEAR, BUT PERHAPS OPEN TO REVISITING THAT
23	IN A SUBSEQUENT PERIOD.
24	MR. TORRES: I DON'T THINK HE'S AWARE THAT
25	THE BOARD ALREADY VOTED TO APPROVE IT.

1	CHAIRMAN GOLDBERG: I CAN'T SPEAK TO HIS
2	UNDERSTANDING.
3	CHAIRMAN KLEIN: ART, HE VOTED IN
4	OPPOSITION TO THE STUDY.
5	MR. TORRES: I KNOW, BUT THE BOARD HAS
6	ALREADY VOTED, SO WE WOULD HAVE TO REVISIT IT WITH A
7	SEPARATE MOTION, CORRECT?
8	CHAIRMAN KLEIN: THAT'S CORRECT. AND IT
9	DOESN'T APPEAR THAT HE REALIZES THAT IT'S PAID FOR
10	THROUGH DONOR FUNDS BECAUSE HE'S USING THE WORD
11	TAXPAYER-RAISED FUNDS FROM THAT QUOTE. SO WE, IN
12	FACT, ARE NOT USING TAXPAYER MONEY IN THIS TIME OF
13	CONSTRAINT. THAT'S THE REASON THE BOARD VOTED FOR A
14	HUNDRED PERCENT OF THESE FUNDS TO COME OUT OF DONOR
15	FUNDS.
16	MR. TORRES: I WAS SENSITIVE TO DUANE'S
17	E-MAIL, SO I'LL TALK TO HIM AS WELL. I KNOW DR.
18	TROUNSON HAS COMMENTS AS WELL.
19	CHAIRMAN GOLDBERG: DR. TROUNSON.
20	DR. TROUNSON: THANK YOU, MICHAEL. THE
21	STAFF HAVE WORKED REALLY HARD ON THIS, AND I ASKED
22	FOR SOME PRETTY DEEP CUTS RIGHT ACROSS THE WHOLE OF
23	THE ORGANIZATION, INCLUDING TRYING TO PERSUADE THE
24	CHAIR TO CUT DEEPLY AS WELL. SO EVERYBODY HAS HAD
25	TO REALLY PROVIDE ME AND THE TEAM WITH A REASONED
	23

1	ARGUMENT FOR ANY CHANGES REALLY TO THE BUDGET.
2	BUT I WOULD SAY THAT WE REMAIN WELL BELOW
3	THE 6 PERCENT, BUT NEVERTHELESS I REMAIN CONCERNED
4	ABOUT THIS. ONCE YOU ENABLE AN INCREASE IN STAFF,
5	YOU START TO APPROACH 6 PERCENT. AND IN MY VIEW
6	THIS IS ON ONE HAND, WHILE WE'RE ABLE TO SPEND DONOR
7	MONEY, THAT'S SAVING CONSIDERABLY ON THE BOND
8	FUNDING MONEY. WE WILL HAVE TO TAKE THIS AS A
9	PRIORITY TO RAISE DONOR MONEY IN THE FUTURE IF WE'RE
10	GOING TO TRY AND REMAIN UNDER THIS 6 PERCENT. I
11	WANT THE BOARD TO UNDERSTAND THE NEED FOR THAT AND
12	TAKE THAT ON SERIOUSLY BECAUSE THE BUDGET TO REMAIN
13	UNDER 6 PERCENT WILL REQUIRE VERY CAREFUL MANAGEMENT
14	OR THE ADDITIONAL ADDITION OF MONEY THAT'S AVAILABLE
15	TO US PERHAPS BY DONATION.
16	CHAIRMAN GOLDBERG: THANK YOU. MELISSA,
17	CAN YOU CIRCULATE FOR PUBLIC COMMENT AT THE VARIOUS
18	SITES, PLEASE?
19	MS. KING: IS THERE ANY PUBLIC COMMENT
20	HERE AT THE CIRM IN SAN FRANCISCO? OKAY. ANY
21	PUBLIC AT ROANOKE STREET IN SAN FRANCISCO?
22	MR. SHEEHY: NO PUBLIC HERE.
23	MS. KING: ANY PUBLIC AT KLEIN FINANCIAL
24	CORPORATION?
25	CHAIRMAN GOLDBERG: NO.

1	MS. KING: ANY PUBLIC AT THE REEVE IRVINE
2	RESEARCH CENTER?
3	DR. STEWARD: NO PUBLIC.
4	MS. KING: ANY PUBLIC AT THE SCRIPPS
5	RESEARCH INSTITUTE?
6	DR. BLOOM: NO PUBLIC.
7	MS. KING: THAT'S IT, MICHAEL.
8	CHAIRMAN GOLDBERG: DO WE NEED A MOTION,
9	JAMES, TO VOTE?
10	MR. HARRISON: MICHAEL, BY MY COUNT YOU'RE
11	ONE MEMBER SHY OF A QUORUM. IF YOU'D LIKE, YOU CAN
12	GET A SENSE OF THE COMMITTEE.
13	MS. KING: JAMES, I FORGOT TO ASK ABOUT
14	MARCY FEIT'S SITE, VALLEY CARE HEALTH SYSTEM.
15	MARCY, DO YOU HAVE ANY PUBLIC WITH YOU?
16	MS. FEIT: NO, I DON'T.
17	MS. KING: GO AHEAD.
18	MR. HARRISON: MICHAEL, WE'RE ONE MEMBER
19	ONE SHY OF A QUORUM, SO WHAT I'D SUGGEST IS THAT YOU
20	GET A SENSE OF THE COMMITTEE, WHICH YOU CAN REPORT
21	TO THE BOARD.
22	CHAIRMAN GOLDBERG: THANK YOU, JAMES. SO
23	I GUESS THE QUESTION BEFORE THE COMMITTEE MEMBERS IS
24	WHETHER THEY'RE IN SUPPORT OF THE BUDGET AS
25	PRESENTED. OBVIOUSLY IT WILL BE RE-PRESENTED WITH
	25

1	SOME OF THE COMMENTS AND ADJUSTMENTS THAT WERE
2	DISCUSSED OVER THE PAST 40 MINUTES, BUT I'D LIKE TO
3	FIND OUT WHETHER PEOPLE ARE COMFORTABLE WITH IT OR
4	WHETHER THERE ARE OBJECTIONS.
5	MR. TORRES: I THINK WITHOUT OBJECTION, WE
6	MOVE TO A CONSENSUS.
7	CHAIRMAN GOLDBERG: ARE THERE ANY
8	OBJECTIONS? HAVING HEARD NONE, I WOULD AGREE WITH
9	YOUR COMMENT, SENATOR TORRES. PRESCIENT AS ALWAYS.
10	I'D LIKE TO MOVE TO THE NEXT AGENDA ITEM
11	AND ASK ELONA BAUM TO DISCUSS AMENDMENTS TO THE LOAN
12	ADMINISTRATION POLICY.
13	MS. BAUM: THANK YOU VERY MUCH. I'VE
14	ASKED SCOTT TO TAKE THE LABORING OAR ON THIS, SCOTT
15	TOCHER. I MIGHT INTERJECT SOME COMMENTS AS
16	APPROPRIATE.
17	MR. TOCHER: THANKS, ELONA, AND JAMES AS
18	WELL, AS NECESSARY. SORT OF FIRST ON A POINT OF
19	PROCESS, AS THE SUBCOMMITTEE MEMBERS WILL RECALL,
20	THIS IS AN ONGOING EFFORT TO REFINE THE LOAN
21	ADMINISTRATION POLICY WHICH MOST RECENTLY WAS
22	CONCLUDED IN NOVEMBER OF LAST YEAR IN ORDER TO HAVE
23	A POLICY IN PLACE FOR IPERIAN AND OTHER LOAN
24	APPLICANTS. SO WHAT WE'RE DOING HERE TODAY IS TO
25	CONSIDER CERTAIN ISSUES THAT WERE TABLED AT THE TIME

1	AS WELL AS TO INCORPORATE ADDITIONAL AMENDMENTS TO
2	THE POLICY THAT HAVE ALREADY BEEN CONSIDERED BY THE
3	BOARD AS A WHOLE. AND THEN FINALLY TO CONSIDER A
4	THIRD SET OF ISSUES THAT HAVE BEEN DEVELOPED AND
5	AMENDMENTS THAT SEEM NECESSARY SINCE NOVEMBER.
6	THREE PARTS. AND THE POINT OF THIS
7	PARTICULAR MEETING IS TO LOOK AT THIS LANGUAGE AND
8	SEE IF IT IS ACCEPTABLE TO SEND FORWARD TO THE ICOC
9	TO RECOMMENDED THE PROCESS OF OPENING UP THE LAP
10	ONCE AGAIN TO INCORPORATE THESE AMENDMENTS. SO IT
11	REALLY IS THE BEGINNING OF THE BEGINNING, ONCE
12	AGAIN, OF A PROCESS TO FURTHER CLARIFY AND PERFECT
13	THE LOAN ADMINISTRATION PROBABLY.
14	AS A RESULT, THEN, THIS IS NOT THE FIRST,
15	NOR THE LAST TIME YOU WILL SEE ALL OF THESE CHANGES.
16	WELL, THE FIRST, BUT IT WON'T BE THE LAST. AFTER WE
17	INITIATE THE RULEMAKING PROCESS, WE WOULD HAVE
18	ANOTHER, AT LEAST ONE MORE MEETING OF THE
19	SUBCOMMITTEE TO CONSIDER THE PUBLIC COMMENT AND ANY
20	OTHER FURTHER REVISIONS IT WOULD LIKE TO MAKE.
21	SO WITH THAT, I WILL BE REFERRING TO THE
22	COPY THAT I HAVE THAT IS REDLINED, IF YOU WILL, THAT
23	HAS STRIKEOUT AND UNDERLINE TO REFLECT THE
24	AMENDMENTS. DUE TO A TECHNICAL GLITCH ON THE
25	WEBSITE, UP UNTIL A LITTLE WHILE AGO, THE VERSION

1	THAT WAS POSTED REFLECTED THE CHANGES AS IF THEY HAD
2	ALL BEEN ACCEPTED. AND THAT WILL MAKE IT A LITTLE
3	HARDER TO OBSERVE THE CHANGES. I KNOW THAT WE HAVE
4	REPOSTED IT. SO IF YOU ARE ONLINE AND YOU HAVEN'T
5	ALREADY DONE SO, YOU CAN DRAW THE DOCUMENT UP AGAIN
6	AND ACTUALLY OBSERVE THE CHANGES IN MARKED FORMAT.
7	AND I BELIEVE, MELISSA, YOU HAVE SENT IT OUT TO THE
8	SITES AS WELL AS TO THE SUBCOMMITTEE MEMBERS.
9	MS. KING: THEY SHOULD HAVE THE TRACK
10	CHANGES IN FRONT OF THEM.
11	MR. TOCHER: WITH THAT, I THINK THE
12	PROBABLY EASIEST FLOW IS TO JUST TAKE THESE THINGS
13	IN THE ORDER IN WHICH THEY APPEAR IN THE LAP.
14	THE FIRST SUBSTANTIVE AREA BEGINS ON MY
15	PAGE ON PAGE 6, WHICH IS SUBPART D OF THE
16	PROPOSAL OF THE POLICY. AND THIS ADDITIONAL
17	LANGUAGE, THREE PARAGRAPHS, ADDRESSES THE ISSUES OF
18	TRANSFER AND ACQUISITION. SO IN THE EVENT THAT OUR
19	BORROWER EITHER TRANSFERS THE IP TO A THIRD PARTY OR
20	THE BORROWER IS ITSELF ACQUIRED, WE NEEDED TO
21	ADDRESS WHAT WOULD HAPPEN IN THOSE CIRCUMSTANCES IN
22	TERMS OF THE OBLIGATIONS TO REPAY THE LOAN.
23	AND SO WHAT THESE PARAGRAPHS SIMPLY STATE
24	IS THAT IN EITHER EVENT WHERE A CIRM-FUNDED
25	INVENTION IS TRANSFERRED OR WHETHER THE BORROWER

1	ITSELF IS ACQUIRED, THAT THE OBLIGATIONS OF THE LOAN
2	WILL FOLLOW TO THE SUBSEQUENT ACQUIRER. AND,
3	FINALLY, THAT, AND THIS REFLECTS AN EARLIER DECISION
4	OF THE SUBCOMMITTEE, THAT THIS ASSIGNMENT OF
5	TRANSFER TO A SUCCESSOR IN INTEREST WOULD BE SUBJECT
6	TO CIRM'S APPROVAL, BUT THAT THAT APPROVAL WOULD NOT
7	BE UNREASONABLY WITHHELD.
8	IF THERE ARE NO QUESTIONS ON THAT, I WOULD
9	PROCEED TO PAGE 8 OF THE COPY REGARDING LOAN
10	REPAYMENT. THESE PARTICULAR PROVISIONS, WHICH BEGIN
11	ON PAGE 8, FIRST OF ALL, DEFINES THE TERM OF
12	SUCCESS. THIS IS AN IMPORTANT TERM IN THE LOAN
13	BECAUSE, OF COURSE, REPAYMENT OF A PRODUCT-BACKED
14	LOAN IS BASED ON THE SUCCESS OF THE PRODUCT. SO WE
15	HAVE A DEFINITION, THEN, IN PLACE IN ORDER TO
16	IDENTIFY THOSE REVENUE STREAMS OF A LOAN RECIPIENT
17	THAT WILL TRIGGER, FOR INSTANCE, REPAYMENT IF THE
18	LOAN HAS BEEN FORGIVEN.
19	AN IMPORTANT COMPONENT AS WELL OF THIS,
20	WHICH YOU WILL FIND ON THE NEXT PAGE, PROVIDES FOR
21	FLEXIBILITY FOR THE LOAN AGREEMENT TO BE MODIFIED
22	POST-RFA IF THERE IS AGREEMENT BETWEEN THE LOAN
23	RECIPIENT AND THE FINANCE SUBCOMMITTEE. IT'S
24	BELIEVED THAT THIS IMPORTANT FLEXIBILITY WILL ASSIST
25	SORT OF LATE DEVELOPMENTS AND UNANTICIPATED

1	CONSEQUENCES THAT NEITHER PARTY WOULD, OF COURSE,
2	WISH TO SEE SCUTTLE THE DEAL. SO THIS IS A
3	MECHANISM TO ENSURE THAT ALL OPPORTUNITIES ARE
4	AVAILABLE TO CIRM IN ORDER TO CLOSE A LOAN
5	AGREEMENT.
6	DR. TROUNSON: I JUST WONDERED IF THERE'S
7	ANY CONSIDERATION OF ANY INVESTMENT BY THE COMPANY.
8	IS THAT CONSIDERED IN THIS, THE MOMENT OF MONEY THAT
9	THEY'VE INVESTED IN THE PROJECT IF THAT'S NOT
10	CONSIDERED?
11	MR. TOCHER: IN TERMS OF A PAYBACK?
12	DR. TROUNSON: IN TERMS OF THE DEFINITION
13	OF SUCCESS.
14	MR. TOCHER: I SEE. REALLY I THINK THAT
15	THIS PARTICULAR TERM IS RELEVANT TO THE CONTEXT ONLY
16	OF WHAT REVENUE STREAMS THAT ARE COMING TO THE
17	COMPANY ARE WE GOING TO LOOK AT WHEN WE ASSESS
18	WHETHER OR NOT THEY ARE MAKING MONEY ON THE PROJECT.
19	MS. BAUM: IT'S IRRELEVANT.
20	DR. TROUNSON: THANK YOU.
21	MR. TOCHER: TO CONTINUE, ON PAGE 9
22	REGARDING THE INTEREST RATE, THIS IS AN ISSUE THAT
23	WE'VE LOOKED AT FOR SOME TIME AND HAVE CONTINUED
24	SORT OF NOODLING ON TO TRY TO IDENTIFY WHAT THE
25	EASIEST MECHANISM IS FOR THE INTEREST RATE FOR

1	FIVE-YEAR LOAN TERMS. AND WHAT HAS BEEN SETTLED
2	UPON IS TO RECOMMEND TO YOU AND TO THE BOARD THAT
3	THE LIBOR RATE, ONE-YEAR LIBOR RATE, PLUS 2 PERCENT,
4	WHICH WOULD RESET UPON EACH DISTRIBUTION. AND EACH
5	DISTRIBUTION WOULD BE DONE ITSELF ON AN ANNUAL
6	BASIS. I BELIEVE THAT THIS LANGUAGE IMPLEMENTS THE
7	PRIOR DISCUSSIONS OF THE FINANCE SUBCOMMITTEE ON THE
8	SUBJECT.
9	MS. BAUM: I'D LIKE TO ADD THAT THE
10	PRESENT LAP ACTUALLY PROVIDES FOR LIBOR PLUS 2
11	PERCENT, BUT THIS IS REALLY A CLARIFICATION, THAT
12	IT'S THE LIBOR, THE ANNUAL, THE ONE-YEAR LIBOR. AND
13	THE POINT OF RESETTING IS ALSO CLARIFIED WITHIN THIS
14	NEW TEXT.
15	CHAIRMAN KLEIN: IN ORDER TO ACHIEVE
16	ENOUGH REVENUE TO OFFSET THOSE CASES WHERE THE LOANS
17	ARE COMPLETELY WRITTEN OFF BECAUSE OF THE LACK OF
18	SUCCESS, I THINK IT IS IMPORTANT TO PUT A FLOOR ON
19	LIBOR. WE'RE IN ATYPICAL CONDITIONS, 50-YEAR LOWS
20	OR CLOSE TO 50-YEAR LOWS IN LIBOR RATES. AND IT'S
21	QUITE TRADITIONAL IN THE FINANCE INDUSTRY TO HAVE A
22	FLOOR, A VERY REASONABLE FLOOR, LIKE 3.5 PERCENT,
	, , , , , , , , , , , , , , , , , , , ,
23	WOULD STILL CREATE WITH THE 2-PERCENT SPREAD MARKED
23 24	
	WOULD STILL CREATE WITH THE 2-PERCENT SPREAD MARKED

SO HAVING A FLOOR REALLY ASSURES US THAT
THOSE THAT ARE SUCCESSFUL, WE WILL COLLECT ENOUGH
INTEREST THAT WE CAN HELP OFFSET THE RISK OF LOANS
THAT WE HAVE TO WRITE OFF AND HELP REPLENISH OUR
FUNDS. SO I'D LIKE TO KNOW HOW OTHERS FEEL ABOUT
PUTTING A FLOOR ON THE LIBOR RATE.
CHAIRMAN GOLDBERG: I THINK A VOICE I'D BE
MOST INTERESTED IN HEARING FROM ON THIS IS DUANE,
WHOSE VOICE WE DON'T HAVE AVAILABLE AT THE MOMENT.
I UNDERSTAND HE'S TRYING TO PERHAPS JOIN AT THE TOP
OF THE HOUR. MELISSA, CAN YOU PERHAPS SEE AND CHECK
ON HIS AVAILABILITY? IN THE MEANTIME, LET'S
CIRCULATE COMMENTS ON THE OTHER ITEMS DISCUSSED AT
THE VARIOUS SITES FOR BOARD COMMENT.
MR. HARRISON: MICHAEL AND BOB, IF IT'S
HELPFUL, THE CURRENT LIBOR RATE IS .77.
CHAIRMAN KLEIN: THAT'S SEVEN-TENTHS OF 1
PERCENT.
MR. HARRISON: CORRECT.
CHAIRMAN KLEIN: THAT WOULD MEAN THAT WITH
THE 2-PERCENT INCREASE, IT WOULD BE 2.77, WHICH IS
BELOW THE FLOOR THAT WAS DONE IN THE MODELING ON THE
LOAN REPAYMENT PROGRAM TO CREATE A PROGRAM THAT
WOULD PERPETUATE SOME PORTFOLIO SIZE.
MS. BAUM: WHAT WAS THAT FLOOR THAT WAS
32

1	USED FOR THAT CALCULATION? WAS IT THREE OR
2	THREE POINT SOMETHING?
3	CHAIRMAN KLEIN: I WAS SUGGESTING A FLOOR
4	OF THREE AND A HALF ON THE LIBOR RATE.
5	MR. HARRISON: ON LIBOR PLUS TWO, BOB.
6	CHAIRMAN KLEIN: LIBOR PLUS TWO. AND
7	THAT'S QUITE CONSISTENT WITH THE BANKING PRACTICES
8	FOR THE MOST HIGHLY PREFERRED CUSTOMERS IN THE
9	NATION. THEY ARE FACING A FLOOR AS WELL UNLESS, IN
10	FACT, WE HAVE HUNDREDS OF MILLIONS OF BALANCES.
11	THEY'VE GOT A DOLLAR-FOR-DOLLAR OFFSET BALANCE OR
12	SOME OTHER ANOMALY OF THAT KIND INFLUENCING IT, OR
13	THEY HAVE THE ABILITY TO BORROW ON COMMERCIAL PAPER,
14	IN WHICH CASE THEY GET A SPECIAL CATEGORY DISCOUNT.
15	THIS WOULD CERTAINLY LEAVE THE LOAN PROGRAM AS A
16	VERY PREFERRED SOURCE OF FUNDING FOR THOSE BIOTECH
17	COMPANIES THAT ARE TRYING TO PUSH THERAPIES FORWARD
18	AND ARE IN A RISK PROFILE WHERE THERE'S A GREAT
19	BENEFIT TO THE PUBLIC, BUT THEY CAN'T GET THE
20	COMMERCIAL LOAN AT ANYWHERE NEAR THIS.
21	CHAIRMAN GOLDBERG: MELISSA, CAN WE POLL
22	THE BOARD MEMBERS AT THE VARIOUS SITES WITH REGARD
23	TO EVERYTHING BUT THIS, WELL, INCLUDING THIS ISSUE.
24	I'D LIKE TO HEAR FROM DUANE AT THE END BEFORE WE
25	TAKE AN ACTION.

1	MS. KING: ANY COMMENTS HERE AT THE CIRM,
2	SENATOR TORRES?
3	MR. TORRES: NO.
4	MS. KING: ANY COMMENTS AT ROANOKE STREET
5	IN SAN FRANCISCO?
6	MR. SHEEHY: NOT SPECIFICALLY, THOUGH I AM
7	INTRIGUED BY THE IDEA OF A FLOOR. THE INTEREST RATE
8	THAT WE'RE TALKING ABOUT IS MUCH LOWER.
9	MS. KING: ANY COMMENTS AT VALLEY CARE
10	HEALTH?
11	MS. FEIT: NO COMMENTS HERE.
12	MS. KING: OKAY. HOW ABOUT KLEIN
13	FINANCIAL?
14	CHAIRMAN KLEIN: NO ADDITIONAL COMMENTS.
15	MS. KING: DR. STEWARD, ANY COMMENTS UC
16	IRVINE?
17	DR. STEWARD: NO COMMENTS.
18	MS. KING: AND DR. BLOOM, HOW ABOUT YOU?
19	DR. BLOOM: I THINK BOB'S SUGGESTION IS A
20	VERY COGENT ONE, AND HE MADE A GOOD CASE FOR IT.
21	MS. KING: ALL RIGHT. THANK YOU.
22	MICHAEL.
23	CHAIRMAN GOLDBERG: LET'S CIRCULATE FOR
24	ANY PUBLIC COMMENTS.
25	DR. TROUNSON: I THINK IT WOULD BE WISE
	2.4
	34

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	ALSO TO JUST CHECK WITH SOME PEOPLE IN INDUSTRY TO
2	SEE HOW THEY'D RESPOND. I THINK IT SEEMS TO BE VERY
3	REASONABLE AND FAIR, BUT I THINK IT WOULD BE WISE
4	JUST TO JUST TO GET A PLUMBING OF THEIR VIEW.
5	MS. BAUM: AS WE INDICATED BEFORE, THIS IS
6	THE FIRST TIME THAT THIS COMMITTEE WILL BE LOOKING
7	AT THIS PROPOSED SET OF AMENDMENTS. THIS WILL GO
8	OUT, AND I WILL PERSONALLY SOLICIT INPUT FROM
9	INDUSTRY THAT WE'VE BEEN IN TOUCH WITH BEFORE TO
10	MAKE SURE THAT WE GET THE INPUT THAT WE REALLY NEED
11	TO MAKE SURE THAT WE GET A SET OF REGULATIONS THAT
12	ARE WORKABLE.
13	CHAIRMAN GOLDBERG: CHAIRMAN KLEIN. THANK
14	YOU, ELONA.
15	CHAIRMAN KLEIN: FOLLOWING ON ELONA'S
16	COMMENTS, AS THESE, NOT ON THE PRIOR PROPOSALS, BUT
17	CERTAINLY ON THE ALTERNATIVE LOAN FORMAT, I WORK
18	VERY CLOSELY WITH ELONA IN MAKING SURE WE HAD
19	MULTIPLE SOURCES OF INDUSTRY INPUT. SO CERTAINLY,
20	DR. TROUNSON, BEFORE THIS GETS TO THE BOARD, WE'LL
21	DOUBLE-CHECK OURSELVES. AND I WILL BE VERY OPEN,
22	EVEN IF WE APPROVE THIS TODAY, TO ANY INDUSTRY
23	SUGGESTIONS THAT POINT OUT SOME FACTOR THAT I'M NOT
24	AWARE OF. SO WE CAN MODIFY AT THE BOARD IF THE
25	INDUSTRY FEEDBACK PROVIDES SOME DIFFERENT VIEW THAT

1	IS RATIONALLY JUSTIFIED.
2	DR. TROUNSON: THANK YOU.
3	CHAIRMAN GOLDBERG: I'D LIKE TO PROCEED
4	AND LEAVE THAT AGENDA ITEM 4 OPEN UNTIL DUANE ROTH
5	CAN JOIN US, IF HE CAN JOIN US, AND THEN PROCEED TO
6	ITEM NO. 5 AND TURN IT OVER TO CHAIRMAN KLEIN FOR A
7	DISCUSSION OF THE IMPACT OF THE STATE BUDGET ON THE
8	SALE OF BONDS ON BEHALF OF CIRM.
9	MR. TOCHER: MICHAEL, THIS IS SCOTT IN SAN
10	FRANCISCO. WE HAVE JUST A FEW MORE PROVISIONS THAT
11	I WILL TRY TO MOTOR THROUGH IF
12	CHAIRMAN GOLDBERG: I APOLOGIZE.
13	MR. TOCHER: THAT'S ALL RIGHT.
14	CHAIRMAN GOLDBERG: I THOUGHT I SAW A
15	WHITE FLAG RAISED, BUT I GUESS I WAS WRONG.
16	MR. TOCHER: WISHFUL THINKING. MOVING
17	QUICKLY, THEN, TO PAGES 10 TO 11, THESE CHANGES
18	REFLECT CHANGES THAT HAVE BEEN POLICY DECISIONS MADE
19	BY THE ICOC REGARDING SIMPLIFICATION OF OUR WARRANT
20	COVERAGE REQUIREMENTS. FOR INSTANCE, FOR
21	COMPANY-BACKED LOANS, WE HAVE TRIED TO ENTICE
22	FURTHER ANTICIPATION BY LOWERING THE WARRANT
23	COVERAGE TO THE ALTERNATIVE 50 PERCENT IN THE EVENT
24	THAT THE COMPANY IS UNABLE TO QUALIFY FOR A 20- OR
25	25-PERCENT WARRANT COVERAGE.

1	AND IN THE CONTEXT OF PRODUCT LOANS, WHAT
2	WE'VE DONE THERE IS IF THEY CAN'T QUALIFY RATHER
3	IT'S THE LESSER OF EITHER 20 PERCENT OF THE LOAN
4	RECIPIENT SHARES OR AN AMOUNT THAT IS PROPORTIONAL
5	TO CIRM'S FUNDING AT ANY GIVEN DISBURSEMENT. SO THE
6	LANGUAGE THERE PROVIDES AN EXAMPLE SO THAT IF CIRM'S
7	FUNDS REPRESENT 50 PERCENT OF THE PROJECT COST FOR
8	THAT GIVEN DISBURSEMENT PERIOD, THAT WOULD BE THE
9	WARRANT COVERAGE THAT THE BORROWER WOULD HAVE TO
10	PROVIDE.
11	MS. BAUM: AGAIN, THIS WAS ALL DECIDED
12	UPON AS A POLICY MATTER ON THE 27TH OF JANUARY.
13	MR. TOCHER: RIGHT, ELONA, BY THE ICOC.
14	AND THEN YOU WILL SEE ON PAGES 11 TO 14,
15	THAT REALLY IS SIMPLY THE RISK PREMIUM ALTERNATIVE
16	CONCEPT THAT CAME BEFORE THE BOARD AND WAS APPROVED
17	BY THE BOARD ALSO IN JANUARY WITH AN EMERGENCY
18	REGULATION. SO THIS IS THE NECESSARY NEXT STEP IN
19	IMPLEMENTING THAT ON A PERMANENT BASIS BY
20	INCORPORATING THAT INTO OUR LAP. SO THAT'S WHAT
21	THIS LANGUAGE IS.
22	THE RISK PREMIUM, AS YOU WILL RECALL, IS
23	SIMPLY A MULTIPLE PAYBACK BASED ON A TIERED LEVEL OF
24	SUCCESS OF THE PRODUCT WITH DIFFERENT LEVELS OF
25	PAYBACK DEPENDING ON WHETHER, OF COURSE, IT IS A

1	COMPANY-BACKED OR PRODUCT-BACKED LOAN.
2	I DON'T THINK THAT THERE ARE ANY TERRIBLY
3	SIGNIFICANT CHANGES TO WHAT THE BOARD HAD ALREADY
4	APPROVED. I THINK WE JUST CLARIFY THE SUNSET
5	PROVISION, THAT IT WILL APPLY IN ITS ENTIRETY OF
6	THOSE ELIGIBLE AWARDS FOR THE EARLY TRANSLATIONAL
7	III AND THE CIRM DISEASE TEAM THERAPY DEVELOPMENT.
8	MS. BAUM: JUST WITH ALL DUE RESPECT, I
9	WANT TO ACKNOWLEDGE THAT DUANE HAD VOICED SOME
10	CONCERN ABOUT THE SUNSET PROVISIONS, AND WE SHOULD
11	CIRCLE BACK WITH HIM TO GET HIS COMMENT WHEN HE
12	JOINS.
13	CHAIRMAN KLEIN: I THINK IT'S IMPORTANT TO
14	NOTE THAT DUANE HAS OBJECTED TO THE SUNSET PROVISION
15	BEING EXTENDED FOR ENOUGH TIME TO INCLUDE DISEASE
16	TEAMS II AND EARLY TRANSLATION III. THERE WAS A
17	SPECIFIC VOTE IN THIS COMMITTEE ON DISEASE TEAM II
18	AND AT THE BOARD ON DISEASE TEAMS II TO MAKE SURE
19	THAT, IN FACT, WE HAD SUFFICIENT TIME TO TEST THIS
20	PROGRAM ON DISEASE TEAMS II AND TO GET INDUSTRY
21	PARTICIPATION IN DISEASE TEAMS II.
22	SO HE DID VOTE AGAINST HAVING THIS
23	ORIGINALLY INCLUDED, BUT BOTH THIS COMMITTEE AND THE
24	BOARD SPECIFICALLY WERE TRYING TO DESIGN THE SUNSET
25	SO IT OCCURRED AFTER THESE ROUNDS SO THAT WE COULD

1	GET A REASONABLE SAMPLE. OTHERWISE WE DON'T HAVE A
2	LARGE PROGRAM THAT THIS WOULD APPLY TO TO TEST THIS
3	MULTIPLE PAYBACK OPTION IN LIEU OF OR AS AN
4	ALTERNATIVE TO THE WARRANT COVERAGE.
5	MS. BAUM: RIGHT NOW WE ONLY HAVE TWO
6	LOANS.
7	CHAIRMAN KLEIN: TWO LOANS UNDER THE
8	WARRANT PROGRAM, SO THE MULTIPLE PAYBACK WAS AN
9	ATTEMPT TO HAVE A REASONABLE TEST PERIOD. AND THE
10	INDUSTRY WHO ARE IN THE PLANNING GRANTS PHASE FOR
11	DISEASE TEAMS II INDICATED THEY WERE CONCERNED THAT
12	IF THE PROGRAM WERE IF THE DISEASE TEAMS II GOT
13	ANY DELAYS IN IT, THAT THEN THEY WOULD GET ALL THE
14	WAY DOWNSTREAM AND THEIR LOANS WOULD FALL OUTSIDE OF
15	THE SUNSET PERIOD. SO THE ATTEMPT HERE IS TO MAKE
16	SURE THAT THE SUNSET BY DEFINITION INCLUDES DISEASE
17	TEAMS II AND EARLY TRANSLATION III SO WE CAN GIVE
18	THEM ASSURANCES THAT THEY WILL BE ABLE TO
19	PARTICIPATE IN THAT PROGRAM. IS THAT CORRECT,
20	ELONA?
21	MS. BAUM: IT'S ACTUALLY ONE LOAN UNDER
22	THE WARRANTS AND ONE LOAN UNDER THE RISK PREMIUMS.
23	CHAIRMAN KLEIN: OKAY. IS MY DESCRIPTION
24	OF THE SUNSET ISSUE CORRECT?
25	MS. BAUM: ABSOLUTELY.
	20

1	MR. TOCHER: MOVING TO OUR FINAL TWO
2	ISSUES, THESE ARE ISSUES THAT THE FINANCE
3	SUBCOMMITTEE WORKED, GRAPPLED WITH UP THROUGH
4	NOVEMBER, BUT DECIDED TO POSTPONE FINAL DECISIONS ON
5	UNTIL WE COULD INITIATE A NEW PROCESS. SO MUCH OF
6	THIS MAY LOOK FAMILIAR. IN SECTION VII H, BEGINNING
7	ON PAGE 15, WHAT WE HAVE HERE IS THE FORGIVENESS AND
8	RESTATEMENT CIRCUMSTANCES FOR A PRODUCT-BACKED LOAN.
9	AND IN BOTH CASES, WHAT WE TRIED TO DO IS
10	INCORPORATE AN AUTOMATIC MECHANISM FOR EACH, WHICH I
11	BELIEVE REFLECTS WHERE THE FINANCE SUBCOMMITTEE WAS
12	HEADED IN NOVEMBER.
13	SO, IN ESSENCE, THERE ARE THREE
14	REQUIREMENTS FOR FORGIVENESS, AND THEY ARE THAT,
15	FIRST, THE BORROWER MUST BE IN COMPLIANCE WITH ALL
16	REPORTING REQUIREMENTS. SECONDLY, THAT THE BORROWER
17	ABANDONS THE PROJECT AND SUBMITS A DECLARATION TO
18	CIRM STATING THAT AND DOES NOT RESUME ANY WORK ON
19	THE PROJECT. AND THIRD, THAT THE BORROWER IS PAID
20	UP IN PRINCIPAL AND INTEREST ON THE LOAN UP TO ANY
21	AMOUNT OF REVENUE THAT HAS BEEN GENERATED SO FAR BY
22	THE PROJECT. SO THEY ARE CURRENT WITH WHATEVER
23	FINANCIAL OBLIGATION THEY HAVE TO CIRM. SO UNDER
24	THOSE CIRCUMSTANCES, THE FORGIVENESS WOULD BE
25	AUTOMATIC.

1	IN SUBDIVISION 2, THEN THAT DESCRIBES THE
2	CIRCUMSTANCES WHERE REINSTATEMENT WOULD BE
3	AUTOMATIC. AND THAT, IN ESSENCE, IS WHEN THE
4	BORROWER OBTAINS ADDITIONAL REVENUE. AND IN THAT
5	CIRCUMSTANCE, THE BORROWER MUST NOTIFY CIRM, AND THE
6	LOAN WILL BE REINSTATED UPON TERMS APPROVED BY THE
7	FINANCE SUBCOMMITTEE WITH THIS CAREFUL DRAW YOUR
8	ATTENTION TO THIS ADDITION. THAT THE INTEREST RATE
9	WOULD NOT BE HIGHER THAN IN THE ORIGINAL LOAN. SO
10	THAT IS SOMETHING NEW FROM PERHAPS WHAT WE
11	CONSIDERED LAST NOVEMBER, AND IT PROBABLY WOULD BE
12	AN IMPORTANT ISSUE OF FAIRNESS TO BORROWERS.
13	CHAIRMAN KLEIN: COULD YOU EXPLAIN THAT
14	POINT AGAIN? WHAT DID YOU JUST SAY, SCOTT?
15	MR. TOCHER: THAT THE REINSTATEMENT IS
16	AUTOMATIC, AND THE FINANCE COMMITTEE WILL APPROVE
17	THE TERMS OF THE REINSTATED LOAN. THE ONLY CAVEAT
18	IS THAT THE INTEREST RATE THAT WOULD OTHERWISE BE
19	THE SUBJECT OF AMENDMENT BY THE FINANCE
20	SUBCOMMITTEE, THAT WILL BE FIXED AT THE RATE THAT IT
21	WAS IN THE ORIGINAL LOAN.
22	MS. BAUM: OR USING THE SAME FORMULA, SO
23	IF IT'S LIBOR, THE LIBOR RATES WOULD APPLY.
24	MR. TORRES: THERE'S BEEN NO CHANGES TO
25	THE SUBORDINATION ISSUE THAT I CAN SEE?

1	MS. BAUM: NO.
2	MR. TORRES: SO YOU STILL HAVE CONSENT OF
3	THE FINANCE SUBCOMMITTEE BASED UPON THE
4	RECOMMENDATION OF THE PRESIDENT STILL IN TACT?
5	MS. BAUM: YES.
6	MR. TOCHER: AND THEN, FINALLY, THE
7	SUBPART VII J IS THE LOAN APPLICATION PROCESS.
8	AGAIN, WE WORKED ON THIS THROUGH LAST NOVEMBER.
9	PRETTY STRAIGHTFORWARD. IT JUST CLARIFIES THAT THE
10	CIRCUMSTANCES OR ELEMENTS THAT MIGHT BE GROUNDS FOR
11	DENIAL OF AN AWARD OF A LOAN AWARD. SO THOSE ARE
12	FINANCIAL GROUNDS, BANKRUPTCY INSOLVENCY, OR FAILURE
13	TO MEET INDUSTRY STANDARDS FOR FINANCIAL PRACTICES.
14	PART 2, SCIENTIFIC REVIEW. JUST SIMPLY AN ALERT
15	THAT THE LOAN AWARDS ARE, DESPITE WHATEVER FINANCIAL
16	HEALTH THEY MAY HAVE OR PROPRIETY, THERE'S STILL A
17	SCIENTIFIC MERIT REVIEW THAT THE APPLICATION WILL BE
18	SUBJECT TO.
19	AND THEN FINALLY, THAT UNDER PART 3, THE
20	FINANCIAL FEASIBILITY REVIEW, TO MAKE CLEAR THAT
21	CIRM WILL DEDUCT THE COST OF THE FINANCIAL DUE
22	DILIGENCE FROM THE INDIRECT COSTS THAT ARE AWARDED
23	TO THE BORROWER. AND SO WITH THAT
24	MR. TORRES: ONE FINAL QUESTION. ARE WE
25	GOING TO PROVIDE A LIST OF THOSE FINANCIAL SERVICES

1	PROVIDERS?
2	MS. BAUM: RIGHT NOW WE ONLY HAVE ONE
3	UNDER CONTRACT.
4	MR. TORRES: SO THEY WOULD BE REQUIRED TO
5	USE THAT PROVIDER?
6	MS. BAUM: YES.
7	MR. TOCHER: I THINK AT THIS POINT I'M
8	AWARE WE DO NOT HAVE A QUORUM, BUT PERHAPS IT MIGHT
9	BE HELPFUL TO GET A SENSE OF THE COMMITTEE IF THIS
10	IS SOMETHING THEY'D LIKE TO MOVE FORWARD WITH AND
11	RECOMMEND THAT THE ICOC USE THIS AS A TEMPLATE FOR
12	INITIATING THE RULEMAKING PROCESS.
13	CHAIRMAN GOLDBERG: WITH THE EXCEPTION OF
14	THE WHO'S CALLING IN PLEASE?
15	LAUREN: THIS IS LAUREN FOR DUANE ROTH.
16	HE'LL BE HERE IN A MINUTE.
17	CHAIRMAN GOLDBERG: WELL, IT'S PROBABLY
18	WORTH WAITING FOR DUANE HERE.
19	(PAUSE IN PROCEEDINGS.)
20	MS. KING: MICHAEL, AS SENATOR TORRES HAS
21	SUGGESTED, WE'LL CHECK FOR PUBLIC COMMENT AS WE WAIT
22	FOR MR. ROTH.
23	ARE THERE ANY PUBLIC COMMENTS HERE OR
24	COMMENTS FROM MY ILLUSTRIOUS FELLOW STAFF MEMBERS
25	THAT ARE ATTENDING THE MEETING AT THE CIRM? ANYONE?

	DARRISTERS REPORTING SERVICE
1	ANYONE? NO. OKAY.
2	MR. TORRES: THEY'RE JUST ILLUSTRIOUS.
3	MS. KING: THEY'RE JUST ILLUSTRIOUS AND
4	THIS INFORMATION IS TOO EXCITING.
5	ANY PUBLIC WE DON'T HAVE ANY PUBLIC AT
6	ROANOKE STREET, CORRECT?
7	MR. SHEEHY: CORRECT.
8	MS. KING: HOW ABOUT AT KLEIN FINANCIAL
9	CORPORATION? HAVE ANY PUBLIC MEMBERS JOINED YOU?
10	CHAIRMAN KLEIN: NO.
11	MS. KING: HOW ABOUT AT UC IRVINE WITH DR.
12	STEWARD?
13	DR. STEWARD: NO PUBLIC HERE.
14	MS. KING: DR. BLOOM, ANY PUBLIC WITH YOU
15	AT THE SCRIPPS RESEARCH INSTITUTE?
16	DR. BLOOM: NONE.
17	MS. KING: ALL RIGHT. MARCY FEIT, AT
18	VALLEY CARE HEALTH SYSTEM, ANY PUBLIC WITH YOU?
19	MS. FEIT: NO.
20	MS. KING: SO WE'VE CHECKED FOR PUBLIC
21	COMMENTS. LAUREN, THANK YOU SO MUCH FOR CONNECTING
22	DUANE AS SOON AS HE'S READY. I BELIEVE A
23	COLLEAGUE WE COULD HAVE THAT'S UP TO MICHAEL.
24	WE COULD MOVE ON TO THE NEXT ITEM AND HAVE
25	CHAIRMAN GOLDBERG: I'D RATHER NOT START
	44

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	THAT. DO WE EXPECT DUANE TO BE ON SHORTLY?
2	LAUREN: YES. ANY SECOND NOW.
3	CHAIRMAN GOLDBERG: FOR ANYONE WHO'S
4	FEELING ANXIOUS, THIS IS A GOOD OPPORTUNITY TO
5	BREATHE.
6	(PAUSE IN PROCEEDINGS.)
7	CHAIRMAN GOLDBERG: WE'LL WAIT FOR ANOTHER
8	60 SECONDS, AND THEN WE'LL PROCEED TO AGENDA ITEM 5.
9	CHAIRMAN KLEIN IS WARMING UP IN THE BULLPEN.
10	MR. TORRES: WATCH OUT FOR HIS OBLIQUES.
11	CHAIRMAN GOLDBERG: OKAY. CHAIRMAN KLEIN,
12	PLEASE LEAD US THROUGH AGENDA ITEM NO. 5.
13	CHAIRMAN KLEIN: THIS IS AN INFORMATIONAL
14	ITEM. I'M JUST DRAWING TO THE ATTENTION OF THE
15	BOARD THAT TOMORROW I WILL BE IN SACRAMENTO FOR A
16	MEETING OF THE CALIFORNIA STEM CELL RESEARCH AND
17	CURES BOND COMMITTEE, WHICH INCLUDES THE TREASURER,
18	THE STATE DIRECTOR OF FINANCE ON BEHALF OF THE
19	GOVERNOR, AND THE CONTROLLER, AS WELL AS I SERVE ON
20	THAT WITH TWO APPOINTMENTS. DR. PRIETO IS GOING TO
21	BE THERE. AND BECAUSE THIS IS NOT EXPECTED TO BE A
22	CONTENTIOUS MEETING, WE WILL BE ONE SHORT IN OUR
23	REPRESENTATION, BUT WE ARE ENTERING THIS MEETING FOR
24	AN AUTHORIZATION OF 343 MILLION OF ADDITIONAL BONDS
25	TO BE ISSUED.
	ΛΓ

1	THIS IS PURSUANT TO AN AUGUST 2010 REQUEST
2	I MADE LOOKING FORWARD. WE HAD ACTUALLY AT THE TIME
3	OF THAT REQUEST EXPECTED THAT IN THE FALL/WINTER OF
4	2011 THAT WE WOULD BE IN LINE FOR A VERY SUBSTANTIAL
5	ADDITIONAL BOND ISSUE. THAT HAS BEEN CLOUDED. WE
6	ARE GOING TO REMAIN OPTIMISTIC THAT WE WILL GET A
7	SIGNIFICANT BOND ALLOCATION, BUT CERTAINLY WE AT
8	THIS MOMENT DO NOT BELIEVE IT WILL BE THE ENTIRE 343
9	MILLION. IT SHOULD PROBABLY, WE WOULD EXPECT, BE
10	SIGNIFICANTLY LESS THAN THAT, AND THEN WE WOULD NEED
11	SOMETHING ADDITIONAL IN THE SPRING OF 2012 TO CARRY
12	US THROUGH THE 2012-13 FISCAL YEAR.
13	IT SHOULD BE REMEMBERED THAT BECAUSE OF
14	THE LARGE COLLABORATIVE TEAMS WE BUILD IN CALIFORNIA
15	FOR DISEASE TEAMS, FOR EXAMPLE, OR LARGE
16	COLLABORATIVE TEAMS THAT ARE NECESSARY FOR CLINICAL
17	TRIALS, AND THE INTERNATIONAL TEAMS THAT WE NEED TO
18	MAKE CERTAIN THAT WE RETAIN A WORKING RESERVE SO
19	THAT WE PROVIDE ASSURANCES TO THESE TEAMS THAT THIS
20	EXTRAORDINARY EFFORT THEY PUT TOGETHER TO BRING
21	TOGETHER INSTITUTIONS AND SPECIAL EXPERTISE IS NOT
22	DEFEATED, ALTHOUGH WE HAVE AN APPROVED LOAN OR
23	GRANT.
24	SO FOR THAT MATTER, IT'S IMPORTANT TO THE
25	INDUSTRY AS WELL. SO IT'S GOING TO BE A VERY

1	IMPORTANT PERIOD. THIS IS THE FIRST STEP IN THIS
2	PROCESS. AND IF YOU SEE AN APPROVAL OF THE \$343
3	MILLION AUTHORIZATION, DON'T CELEBRATE YET. IT'S
4	JUST THE FIRST, BUT IMPORTANT STEP IN THIS PROCESS
5	THAT BACK IN DECEMBER I INDICATED WE WOULD TRY AND
6	GET ACCOMPLISHED WHILE I WAS STILL A MEMBER OF THIS
7	COMMITTEE AND SERVING IN THIS SHORT PERIOD OF THE
8	FIRST SIX MONTHS OF THIS YEAR AS THE CHAIR.
9	THE STATE'S ANNOUNCEMENT ON THE BUDGET AND
10	THE IMPACT ON RATING AGENCIES AT THE STATE LEVEL
11	HAVE NOW BEEN COMPOUNDED BY ADDITIONAL CONSERVATISM
12	NATIONALLY REFLECTED BY THE STANDARD AND POORS
13	ANNOUNCEMENT OF A NEGATIVE RATING ON THE U.S.
14	TREASURY BONDS YESTERDAY. AND I AM HOPEFUL THAT
15	THEY CAN FIND AN EFFECTIVE WAY TO REACH A COMPROMISE
16	ON THIS BUDGET FAIRLY EARLY IN THIS SESSION. AS IT
17	IS LATER INTO THE YEAR, IT PUSHES THE STATE UP
18	AGAINST THE END OF THE YEAR AND THE STATE HAS
19	HISTORICALLY NOT GOTTEN SOME OF THEIR BEST PRICING
20	AT THE END OF THE YEAR. DECEMBER IS A TOUGH MONTH,
21	BUT LAST YEAR THEY DID ISSUE IN DECEMBER.
22	SO JUST TO KEEP YOU ABREAST OF WHAT'S
23	HAPPENING, THAT'S A QUICK OVERVIEW.
24	CHAIRMAN GOLDBERG: THANK YOU. ANY
25	QUESTIONS FOR CHAIRMAN KLEIN?

1	CHAIRMAN KLEIN: I WOULD SAY, JUST AS A
2	POSTSCRIPT TO THAT, THAT HISTORICALLY IN THE CASH
3	FLOWS THAT HAVE BEEN CARRIED INTERNALLY, THERE'S
4	BEEN ABOUT A \$15 MILLION LAG IN GRANTS APPROVED FOR
5	A SPECIFIC PERIOD AND THE PAPERWORK BEING COMPLETED
6	AND THE GRANTS PAID OUT. SO IN OUR CASH FLOWS
7	HISTORICALLY THE DEMAND FOR FUNDS HAS BEEN REDUCED
8	BY THAT 15 MILLION ON A FAIRLY CONSISTENT BASIS OVER
9	TIME.
10	AS INSTITUTIONS IN THE STATE HAVE THEIR
11	BUDGETS CUT DOWN, WE CAN EXPECT THAT THEY'RE GOING
12	TO DEMAND THEIR PI'S ARE MORE TIMELY IN FILLING OUT
13	ALL THE PAPERWORK AND PROVIDING THAT THEY MEET ALL
14	THE REQUIREMENTS AND TIGHTENING UP ON THE CASH FLOW.
15	SO IT'S MY EXPECTATION THAT OUR FUNDS THAT ARE
16	AVAILABLE FOR FUNDING ARE ACTUALLY GOING TO SHRINK
17	ON A CASH FLOW BASIS BECAUSE PEOPLE ARE GOING TO
18	APPLY EARLIER AND GET FUNDED EARLIER THAN
19	HISTORICALLY HIS BEEN TRUE.
20	SO WE'LL GET MORE CONSERVATIVE IN OUR CASH
21	FLOWS, AND IT IS VERY IMPORTANT, THEREFORE, TO
22	CREATE AN APPROPRIATE RESERVE, UNDERSTANDING THAT
23	THAT IS GOING TO BE ANOTHER FACTOR INFLUENCING OUR
24	FUND AVAILABILITY.
25	CHAIRMAN GOLDBERG: THANK YOU.
	48
	TO

1	MR. TORRES: MR. GOLDBERG, MR. CHAIRMAN,
2	JUST GIVEN THE TIME SINCE DUANE IS NOT
3	MR. ROTH: I AM HERE.
4	MR. TORRES: OH, GREAT.
5	CHAIRMAN GOLDBERG: HAVING SAID THAT,
6	PLEASE PROCEED WITH YOUR COMMENTS.
7	MR. ROTH: WHOSE COMMENT ARE YOU LOOKING
8	FOR?
9	CHAIRMAN GOLDBERG: SENATOR TORRES.
10	MR. TORRES: I'M GLAD THAT DUANE IS HERE,
11	SO I DEFER TO HIM.
12	CHAIRMAN GOLDBERG: DUANE, JUST AS A
13	RECAP, WE COVERED DISCUSSION OF THE BUDGET AND
14	POLLED THE MEMBERS AS TO THEIR SENSE OF SUPPORT OR
15	OBJECTION TO THE BUDGET AS PROPOSED. THERE WAS AN
16	EXTENSIVE DISCUSSION AND SOME CLARIFICATIONS ABOUT
17	WHAT SOME OF THE BUDGETED INCREASE ITEMS WOULD BE
18	FUNDED THROUGH SPECIFICALLY DONOR FUNDS FOR THE IOM
19	STUDY AND THE WORLD STEM CELL CONFERENCE ATTENDANCE
20	BY PATIENT ADVOCATES.
21	AND WITH THAT CLARIFICATION AND CONSEQUENT
22	ADJUSTMENT TO THE ACTUAL YEAR-OVER-YEAR INCREASE IN
23	CORE SPENDING, THERE WAS CONSENSUS TO SUPPORT THAT
24	BUDGET. I DID READ INTO THE RECORD YOUR DISSENT
25	WITH RESPECT TO THE IOM STUDY, BUT THERE WERE
	49

1	QUESTIONS AS TO WHETHER OR NOT YOU UNDERSTOOD THAT
2	THAT WAS BEING PROPOSED TO BE FUNDED BY DONOR FUNDS
3	WHICH HAVE ALREADY BEEN RAISED AS OPPOSED TO
4	TAXPAYER-DERIVED FUNDS. AND SO LET ME ASK YOU TO
5	ADDRESS THAT.
6	MR. ROTH: YES. AND I UNDERSTAND AND, IN
7	FACT, OFTEN WE REFER TO DONOR FUNDS FOR THINGS LIKE
8	THIS. AND I JUST WOULD POINT OUT THAT THOSE MONIES
9	I THINK WE SHOULD VIEW JUST AS WE DO THE MONEY FROM
10	BOND SALES, THAT IT'S THERE, IT'S THERE FOR A
11	PURPOSE, AND IT SHOULD BE A PRETTY HIGH STANDARD IN
12	THESE ECONOMIC TIMES BEFORE WE SPEND MONEY ON THINGS
13	THAT WOULD BE POTENTIALLY NICE TO HAVE, BUT MAYBE
14	NOT ESSENTIAL. SO WHILE I SUPPORT THE GRANTS FOR
15	ATTENDANCE AT THE MEETING, I DON'T THINK, WITHOUT
16	MORE DISCUSSION, THAT I WANT TO GET BEHIND AN
17	EXPENSIVE ADDITIONAL STUDY ON THIS ORGANIZATION.
18	I THINK WE HAVE ONE THAT HAS BEEN DONE.
19	IT WAS DONE VERY WELL, AND IT CAME OUT VERY WELL FOR
20	US. SO I DON'T SEE THE BENEFIT OF AN ADDITIONAL
21	STUDY.
22	CHAIRMAN GOLDBERG: THE SECOND POINT THAT
23	CAME UP IN DISCUSSION WAS THAT THE BOARD HAD
24	APPROVED THE IOM STUDY. AND SO THE MECHANICS OF
25	REVISITING THAT AREN'T SIMPLY TO BE ADDRESSED

1	THROUGH THE REVIEW OF THE BUDGET, BUT, IN FACT,
2	WOULD REQUIRE A SEPARATE MOTION TO THE BOARD.
3	MR. ROTH: I'LL BE SATISFIED IF THE FULL
4	BOARD HAS A DISCUSSION ON THAT ITEM. I WOULD NOT
5	VOTE AGAINST THE BUDGET BECAUSE THAT ITEM IS IN
6	THERE BECAUSE I DON'T VIEW THAT NECESSARILY AS
7	ENDORSING EVERY ITEM IN THE BUDGET PER SE.
8	CHAIRMAN KLEIN: THE FINANCE COMMITTEE
9	ACTED, THE BOARD ACTED ON THIS ITEM, AND THE
10	CONTRACT WITH THE IOM HAS BEEN EXECUTED. SO, YOU
11	KNOW, AT THIS POINT ON A PROSPECTIVE BASIS, WE CAN
12	HAVE A DISCUSSION, BUT WE HAVE A CONTRACT WITH THE
13	IOM THAT WAS ENTERED INTO AFTER MONTHS OF
14	DISCUSSIONS AND CONTRACT NEGOTIATIONS AFTER THE
15	BOARD ACTION.
16	MS. KING: MICHAEL, DID YOU WANT TO MOVE
17	ON TO THE LAP ITEM AND GET DUANE'S COMMENTS ON THAT
18	AND MAYBE HAVE A VOTE ON THAT SINCE WE NOW HAVE A
19	QUORUM?
20	CHAIRMAN GOLDBERG: I ALSO YES, I THINK
21	I CAN ACCURATELY REFLECT TO THE FULL BOARD THE
22	DISCUSSION OF THE COMMITTEE WITH RESPECT TO THE
23	BUDGET.
24	SO, DUANE, IN THE DISCUSSION OF THE
25	VARIOUS AMENDMENTS TO THE LAP, WE ALSO, IN ADDITION

1	TO THE COMMENTS THAT YOU HAD SEEN, I GUESS, ELONA
2	REFLECTED YOUR SENSE OF THE OPTIONAL RISK PREMIUM.
3	MR. ROTH: THE TIME FRAME?
4	CHAIRMAN GOLDBERG: CORRECT. AND IF
5	ANYONE, I'LL LEAVE IT TO MEMBERS OF THE COMMITTEE IF
6	ANYONE WOULD LIKE TO HEAR DUANE SPEAK TO THAT
7	SPECIFICALLY. IF NOT, WE CAN MOVE ON TO THE ONE
8	OTHER OPEN ISSUE THAT WE PUT A PIN IN FOR YOUR
9	COMMENT. OTHER BOARD MEMBERS, ANY DESIRE TO HEAR
10	FURTHER ON ITEM NO. 7 IN THE LAP CONCERNING THE
11	EXTENSION OF THE OPTIONAL RISK PREMIUM BEYOND 18
12	MONTHS? HEARING
13	CHAIRMAN KLEIN: DUANE, YOU SHOULD KNOW
14	THAT THE DISCUSSION WAS THAT THE INTENT OF THIS
15	PROVISION WAS MAKE SURE THAT DISEASE TEAM II AND
16	EARLY TRANSLATION III CAME WITHIN THAT TIME FRAME
17	EVEN THOUGH THEY MAY BE DELAYED. CERTAIN INDUSTRY
18	PARTICIPANTS WHO WANTED TO PARTICIPATE IN THOSE
19	ROUNDS AND ARE PARTICIPATING IN THE EARLY STAGES OF
20	THOSE ROUNDS WANTED TO MAKE SURE THAT IF THERE WAS A
21	DELAY, THEY WOULDN'T GET CUT OFF. AND IN THIS
22	COMMITTEE AND IN THE BOARD PREVIOUSLY, DISEASE TEAM
23	II WAS SPECIFICALLY MENTIONED AS AN INTENTION OF
24	BEING COVERED TO MAKE SURE WE HAD A TEST PERIOD,
25	ACTUAL PROGRAMS OF A SIZE THAT WOULD QUALIFY FOR
	52

1	LOANS UNDER OUR POLICY.
2	MR. ROTH: I THINK THIS IS A DEBATE ABOUT
3	LOANS WITH THIS NEW RISK PREMIUM THAT'S A MULTIPLE
4	OF SALES WHICH WILL COME DECADES FROM NOW VERSUS
5	WHETHER WE WANTED TO STICK TO OUR ORIGINAL WARRANTS
6	THAT MAKE THIS PROGRAM WORK AND WITHOUT THEM, IT
7	DOESN'T REALLY PENCIL. SO THAT WAS MY ONLY AND
8	WE HAD A DISCUSSION. WE STARTED AT A YEAR. I THINK
9	WE COMPROMISED AT 18 MONTHS. AND NOW WHAT IS THE
10	SUGGESTION WE GO TO?
11	CHAIRMAN KLEIN: THAT DISEASE TEAM II AND
12	EARLY TRANSLATION III BE INCLUDED IN THIS PERIOD SO
13	IF THEY GET DELAYED BY A FEW MONTHS, IT DOESN'T
14	KNOCK THEM OUT OF THE 18 MONTHS.
15	MS. BAUM: I'D LIKE TO CLARIFY THAT THE
16	WAY IT'S DRAFTED, IT WOULD ALSO INCLUDE THE TARGETED
17	CLINICAL DEVELOPMENT RFA BECAUSE IT PRECEDES.
18	CHAIRMAN KLEIN: THAT'S WITHIN THE 18
19	MONTHS.
20	MS. BAUM: EXACTLY. I JUST WANTED TO
21	CLARIFY IF THERE'S ANY CONFUSION.
22	CHAIRMAN GOLDBERG: THE OTHER DISCUSSION
23	THAT WE'RE INTERESTED IN YOUR FEEDBACK ON, DUANE,
24	HAD TO DO WITH ESTABLISHING A FLOOR ON THE LIBOR
25	RATE FOR THE LOANS.

1	MR. ROTH: I'M INDIFFERENT ON THAT,
2	MICHAEL.
3	CHAIRMAN GOLDBERG: OKAY. SO WHAT WE
4	DECIDED TO DO
5	MR. ROTH: THE POINT IS THAT INTEREST
6	RATES AND THINGS LIKE THAT HAVE LITTLE BEARING ON
7	THE RETURN HERE.
8	CHAIRMAN GOLDBERG: THAT'S CERTAINLY MY
9	SENSE, BUT ELONA WAS GOING TO POLL THAT QUESTION
10	ALONG WITH SEVERAL OF THE OTHER QUESTIONS THAT CAME
11	UP IN CONNECTION WITH THE REVIEW TODAY WITH MEMBERS
12	OF INDUSTRY AND SOLICIT FEEDBACK FOR THE BENEFIT OF
13	THE BOARD BEFORE THE ICOC TAKES UP A VOTE.
14	CHAIRMAN KLEIN: DUANE, IT WAS A 3.5
15	PERCENT FLOOR. JUST LIBOR RIGHT NOW IS AT .77,
16	SEVEN-TENTHS OF A PERCENT. SO AS STANDARD PRACTICE
17	IN THE BANKING INDUSTRY, AT LEAST CREATE A FLOOR,
18	SOME REASONABLE FLOOR, AT THIS POINT.
19	MR. ROTH: THAT'S FINE.
20	CHAIRMAN GOLDBERG: OKAY. SO, JAMES, DO
21	WE NEED TO TAKE A VOTE ON THE LAP AMENDMENTS?
22	MR. HARRISON: YES, MICHAEL. WE HAVE A
23	QUORUM, SO IF YOU'RE INTERESTED, WE CAN ASK FOR A
24	MOTION TO RECOMMEND THE PROPOSED LAP AMENDMENTS TO
25	THE BOARD CONTINGENT UPON FURTHER DISCUSSION
	54

_	Diministration in the service
1	REGARDING THE INTEREST RATE FLOOR.
2	MR. TORRES: SO MOVED.
3	CHAIRMAN KLEIN: SECOND.
4	MS. KING: THE MOTION IS FROM SENATOR
5	TORRES, AND THE SECOND IS FROM BOB KLEIN.
6	CHAIRMAN GOLDBERG: MELISSA, COULD YOU
7	PLEASE POLL THE BOARD.
8	MS. KING: FLOYD BLOOM.
9	DR. BLOOM: YES.
10	MS. KING: MARCY FEIT.
11	MS. FEIT: YES.
12	MS. KING: MICHAEL GOLDBERG.
13	CHAIRMAN GOLDBERG: YES.
14	MS. KING: BOB KLEIN.
15	CHAIRMAN KLEIN: YES.
16	MS. KING: DUANE ROTH.
17	MR. ROTH: YES.
18	MS. KING: JEFF SHEEHY.
19	MR. SHEEHY: YES.
20	MS. KING: OSWALD STEWARD.
21	DR. STEWARD: YES.
22	MS. KING: ART TORRES.
23	MR. TORRES: AYE.
24	MS. KING: THAT MOTION CARRIES.
25	CHAIRMAN GOLDBERG: THANK YOU. IS THERE
	55

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

ANY OTHER BUSINESS OR COMMENTS FROM ANY OF THE
MEMBERS OF THE SUBCOMMITTEE?
MR. TORRES: THANK YOU, MR. CHAIRMAN AND
THE STAFF.
CHAIRMAN GOLDBERG: THANK YOU. AND I'D
LIKE TO SECOND THAT EXPRESSION OF APPRECIATION TO
THE STAFF FOR AN EXCELLENT BUDGET. I THINK THE KIND
OF BUDGET TIMELINE IN PROCESS WHICH WE WOULD HOPE
WOULD BE REPEATED IN SUBSEQUENT YEARS.
CHAIRMAN KLEIN: SO SENATOR TORRES, THIS
IS BOB. MY UNDERSTANDING IS YOU ARE GOING TO WORK
WITH THE STAFF THERE AT THE AGENCY TO GET OUT A
SUMMARY TODAY THAT POINTS OUT IF YOU BREAK DOWN
THESE PERCENTAGE FACTORS, THAT NET OF THE CRITICAL
PERSONNEL, ADDITIONS SPECIFICALLY AUTHORIZED BY THE
LEGISLATURE, THAT WE'RE ONLY AT ABOUT A 1.3-PERCENT
INCREASE YEAR TO YEAR. IS THAT THE GOAL?
MR. TORRES: 1.3 PERCENT INCREASE? I
THOUGHT IT WAS HIGHER THAN THAT.
CHAIRMAN KLEIN: AFTER DEDUCTING THE
LEGISLATIVE MANDATED STUDY, THE DONOR FUNDS THAT ARE
NOT STATE FUNDS
MR. TORRES: I GET TWO THOSE.
CHAIRMAN KLEIN: AND CALLING OUT THE
9.3 PERCENT OF THE INCREASE IS THE SIX PERSONNEL
56

1	MEMBERS UNDER THE LEGISLATIVE AUTHORIZATION
2	SPECIFICALLY FOR ADDITIONAL STAFF TO DEAL WITH THESE
3	CLINICAL CHALLENGES AND LATER STAGE RESEARCH
4	DEVELOPMENT DISEASE TEAM-TYPE PROGRAMS.
5	MR. TORRES: CORRECT. THEY'RE NODDING IN
6	CONCURRENCE.
7	CHAIRMAN KLEIN: OKAY.
8	CHAIRMAN GOLDBERG: THANK YOU. IF NO
9	OTHER BUSINESS OR COMMENTS, I'D MOVE TO ADJOURN THE
10	MEETING.
11	(THE MEETING WAS THEN ADJOURNED AT
12	11:25 A.M.)
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	57

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE FINANCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON TUESDAY, APRIL 19, 2011, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100